Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Neurology›Condition·Updated Jul 11, 2026·v1

Multiple Sclerosis

Multiple sclerosis (MS) is a chronic immune-mediated demyelinating CNS disease primarily affecting young adults. The 2024 McDonald criteria enable earlier diagnosis by including the optic nerve and κ-free light chains. Management has shifted to early high-efficacy immunotherapy (anti-CD20, natalizumab, cladribine) for active relapsing-remitting MS to prevent disability. Acute relapses are treated with high-dose corticosteroids and plasma exchange if refractory. For progressive forms, ocrelizumab (PPMS) and tolebrutinib (nonrelapsing SPMS) are approved. Comprehensive care requires symptomatic treatment, rehabilitation, comorbidity management, and vaccination optimization. Key biomarkers (sNfL, sGFAP, central vein sign, paramagnetic rim lesions) aid prognosis and treatment decisions.

High Evidence568 references·12,967 words·52 min read·v1
Multiple SclerosisDemyelinating DiseaseNeurologyAutoimmuneDisease-Modifying TherapyRelapsing-Remitting MSSecondary Progressive MSPrimary Progressive MS

Quick Reference

RxDrug of choiceHigh-efficacy anti-CD20 monoclonal antibody: ocrelizumab 600 mg IV every 24 weeks (300 mg day 0 and day 15 initially), ofatumumab 20 mg SC every 4 weeks, or ublituximab 450 mg IV every 24 weeks for active relapsing-remitting MS. Ocrelizumab is also approved for primary progressive MS. Tolebrutinib 60 mg once daily for nonrelapsing secondary progressive MS.
AltAlternativesNatalizumab 300 mg IV every 4 weeks (JCV serology required), cladribine 3.5 mg/kg oral cumulative over 2 years, alemtuzumab 12 mg IV induction (reserved for highly active RRMS after failure), fingolimod 0.5 mg daily, siponimod 2 mg daily (active SPMS), dimethyl fumarate 240 mg twice daily, teriflunomide 14 mg daily (moderate-efficacy for mild disease).
⊘AvoidNon-dihydropyridine calcium channel blockers (diltiazem, verapamil); atacicept (increases relapse rate); high-dose biotin (MD1003, failed phase 3); live-attenuated vaccines during immunosuppressive DMT; fingolimod, cladribine, and alemtuzumab in pregnancy (except special circumstances).
DxTest of choiceBrain MRI with 3D-FLAIR, pre- and post-gadolinium T1-weighted imaging, and T2* susceptibility sequences (SWI/T2*-GRE) to assess dissemination in space and time. Lumbar puncture for CSF oligoclonal bands or κ-free light chain index. Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) for prognosis and treatment stratification.
ScKey scoreExpanded Disability Status Scale (EDSS) for disability staging (0-10); No Evidence of Disease Activity-3 (NEDA-3) as treatment target (no relapses, no sustained progression, no new MRI lesions); Symbol Digit Modalities Test (SDMT) for cognitive screening; Multiple Sclerosis Functional Composite (MSFC) including Timed 25-Foot Walk, 9-Hole Peg Test, and PASAT.
→When to referRefer to MS specialist for diagnostic uncertainty (atypical presentation, inconclusive MRI/CSF), breakthrough disease on moderate-efficacy DMT requiring escalation, consideration of high-efficacy therapy in pregnancy/breastfeeding, aggressive MS variants (Marburg, tumefactive), evaluation for aHSCT, or when multidisciplinary rehabilitation needed for significant disability.
Multiple sclerosis is a treatable CNS demyelinating disease; early diagnosis using 2024 McDonald criteria and initiation of high-efficacy disease-modifying therapy (anti-CD20, cladribine, or natalizumab) in active relapsing disease reduces long-term disability. Acute relapses are managed with high-dose IV methylprednisolone 1 g daily × 3-5 days; steroid-refractory attacks require plasma exchange. For progressive MS, ocrelizumab (PPMS) and tolebrutinib (nonrelapsing SPMS) are evidence-based. Comprehensive care includes symptomatic therapy, rehabilitation, comorbidity management, and vaccination optimization.
Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease of the CNS, typically presenting in young adults with relapsing-remitting episodes. Early diagnosis using the 2024 McDonald criteria and prompt initiation of high-efficacy disease-modifying therapy are critical to prevent irreversible disability accumulation. Management includes acute attack abortion with high-dose corticosteroids, long-term immunotherapy tailored to disease activity, and comprehensive symptomatic and rehabilitative care. Key biomarkers such as serum neurofilament light chain and glial fibrillary acidic protein stratify risk and guide treatment intensity.

Overview and Recommendations

Background

  • •MS is a chronic immune-mediated demyelinating disease of the CNS with a global prevalence of 35.9 per 100,000 (2.8 million people), affecting young adults aged 18-40 years with a female-to-male ratio of 2.8:1. The clinical course is classified into relapsing-remitting MS (RRMS, ~85% at onset), secondary progressive MS (SPMS), primary progressive MS (PPMS), and clinically isolated syndrome (CIS). The 2024 McDonald criteria expanded diagnostic options by adding the optic nerve as a fifth anatomical region and incorporating biomarkers like the central vein sign, paramagnetic rim lesions, and CSF kappa free light chains, enabling earlier and more specific diagnosis.
  • •The paradigm of MS management has shifted from escalation therapy (starting with moderate-efficacy drugs) to early high-efficacy therapy (anti-CD20 antibodies, natalizumab, cladribine) based on evidence that early intensive treatment reduces long-term disability accrual. The concept of progression independent of relapse activity (PIRA) now dominates understanding of disability accumulation, accounting for 78-89% of confirmed disability worsening events in relapsing MS, driven by smoldering compartmentalized inflammation in chronic active lesions with microglial senescence and glymphatic failure.
  • •The immune pathogenesis involves peripheral dysregulation triggered by Epstein-Barr virus infection with molecular mimicry, followed by CNS-compartmentalized B-cell maturation and T-cell cooperation, leading to demyelination, neurodegeneration, and gray matter atrophy. Key effectors include autoantibodies against KIR4.1, complement activation, and activated microglia. Biomarkers such as serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) stratify risk: patients with high levels of both have the highest risk of PIRA (HR 1.43) and benefit most from high-efficacy DMT.
  • •MS is one of the most common causes of neurological disability in young adults. Without treatment, the median time from diagnosis to needing a walking aid (EDSS 6) is approximately 18.5 years, but early high-efficacy therapy can reduce 10-year EDSS by 1 point or more. Modifiable risk factors include smoking, low vitamin D, and obesity; comorbidities (especially cardiometabolic) worsen outcomes. Vaccination is safe and recommended, with ECTRIMS/EAN 2023 consensus guidelines emphasizing optimization before immunosuppressive DMT.

Evaluation

  • •Suspect MS in any young-to-middle-aged adult (peak age 32) presenting with acute or subacute onset of a neurological deficit consistent with CNS demyelination: common presentations include optic neuritis (unilateral vision loss with painful eye movement), brainstem syndromes (diplopia, vertigo, internuclear ophthalmoplegia), transverse myelitis (symmetric or asymmetric weakness, sensory level, bladder dysfunction), or hemispheric syndromes. Also consider in patients with progressive neurologic decline without relapses (PPMS).
  • •Ask about prior episodes of similar deficits, even if completely resolved; symptoms of fatigue, depression, urinary urgency, or Lhermitte sign (electric shock on neck flexion) may precede diagnosis by years. Inquire about family history of autoimmune disease, EBV serostatus (especially infectious mononucleosis), smoking, and vitamin D exposure.
  • •Examine for pyramidal weakness (often asymmetric), spasticity, hyperreflexia, extensor plantar response, sensory loss with dorsal column involvement (vibration, proprioception), cerebellar signs (intention tremor, ataxic gait, dysarthria), and cranial nerve abnormalities including optic atrophy and internuclear ophthalmoplegia (INO). Assess for Lhermitte sign and Uhtoff phenomenon (worsening with heat).
  • •Order brain MRI with 3D-FLAIR, pre- and post-gadolinium T1-weighted images, and T2* susceptibility sequence (SWI/T2*-GRE) to assess for dissemination in space (DIS) and time (DIT). DIS requires T2-hyperintense lesions in at least two of four classic regions: periventricular, juxtacortical/cortical, infratentorial, spinal cord. The 2024 criteria add the optic nerve as a fifth region, assessable by fat-suppressed T2 MRI or optical coherence tomography (OCT) demonstrating ganglion cell-inner plexiform layer (GCIPL) thinning.
  • •DIT can be established by the simultaneous presence of gadolinium-enhancing and non-enhancing lesions on a single scan, or by a new T2 or gadolinium-enhancing lesion on follow-up MRI. The central vein sign (vein transecting ≥40% of lesions) and paramagnetic rim lesions (chronic active lesion marker) increase specificity for MS and are recommended when conventional findings are inconclusive.
  • •Perform lumbar puncture for CSF analysis when MRI is nondiagnostic or if atypical features appear. Test for CSF-specific oligoclonal bands (OCBs) by isoelectric focusing - present in >85% of MS. Alternatively, measure the κ-free light chain index (CSF κ-FLC/serum κ-FLC) with a cutoff of 6.1 (sensitivity 88%, specificity 89%), now accepted as a substitute for OCBs in the 2024 criteria. Also check CSF cell count (mild lymphocytic pleocytosis), protein, and IgG index.
  • •Obtain serum neurofilament light chain (sNfL) as a biomarker of neuroaxonal damage; levels correlate with gadolinium-enhancing lesions and predict future relapses and disability worsening (OR 2.41 for EDSS worsening when >97.5th percentile of healthy controls). Combined sNfL and sGFAP (glial fibrillary acidic protein) stratifies progression risk: high both indicates highest risk of PIRA (HR 1.43) and need for high-efficacy DMT; low both suggests a benign course.
  • •Apply the 2024 McDonald criteria: require demonstration of DIS and DIT, with no better explanation. In patients with a single clinical attack and DIS plus positive CSF (OCBs or κ-FLC), diagnosis can be made even without DIT. The criteria now allow diagnosis in radiologically isolated syndrome (RIS) if DIS plus DIT or positive CSF are met, enabling earlier detection.
  • •Also consider differential diagnoses: neuromyelitis optica spectrum disorder (NMOSD, test serum AQP4-IgG by cell-based assay), MOG antibody disease (MOG-IgG, titer ≥1:128), acute disseminated encephalomyelitis (ADEM with encephalopathy), progressive multifocal leukoencephalopathy (PML, CSF JC virus PCR), neurosarcoidosis (CSF cytokines, biopsy), Susac syndrome (triad of encephalopathy, hearing loss, retinopathy). Exclude cerebral small vessel disease/migraine and other mimics using clinical and imaging features (e.g., absence of central vein sign, lack of DIT).
  • •If initial workup is inconclusive, repeat MRI with contrast at 3-6 months, consider spinal cord MRI (cord lesions improve specificity), and refer to an MS specialist for additional testing such as visual evoked potentials (delayed P100 latency) or OCT with inter-eye GCIPL difference ≥4 μm. Evoked potentials and OCT can help confirm DIS when MRI is equivocal.

Management

  • •For acute relapse management, administer high-dose intravenous methylprednisolone 1 g daily for 3-5 days for moderate-to-severe attacks (motor, visual, brainstem, or coordination deficits that impair daily activities). An oral taper (prednisone 60 mg/day tapered over 2-4 weeks) is optional for incomplete responders. Monitor glucose, blood pressure, electrolytes, and neuropsychiatric effects (insomnia, mood changes).
  • •For steroid-refractory or fulminant attacks (severe myelitis, bilateral optic neuritis, brainstem compromise, or no improvement after 5-7 days of steroids), initiate plasma exchange (5-7 sessions over 10-14 days, 1-1.5 plasma volume per session) - early initiation (<20 days from symptom onset) improves likelihood of response. Plasma exchange is AAN Level B for steroid-resistant relapses.
  • •For aggressive MS variants (Marburg variant, tumefactive demyelination), escalate to cyclophosphamide 600-1000 mg/m² IV monthly or rituximab 1000 mg IV × 2 two weeks apart, in addition to corticosteroids and plasma exchange. For acute seizures in MS, treat the underlying attack with immunotherapy and start an antiseizure medication (e.g., levetiracetam) for symptomatic control.
  • •For long-term disease-modifying therapy (DMT), stratify risk at baseline using clinical relapse frequency, MRI activity (gadolinium-enhancing lesions, new/enlarging T2 lesions), and biomarkers (sNfL, sGFAP). The therapeutic goal is No Evidence of Disease Activity-3 (NEDA-3): no relapses, no sustained disability progression, and no new/enlarging T2 or gadolinium-enhancing lesions.
  • •Initiate early high-efficacy therapy in patients with active disease (frequent relapses, multiple MRI lesions, elevated sNfL): ocrelizumab 300 mg IV day 0 and day 15, then 600 mg IV every 24 weeks; ofatumumab 20 mg SC weeks 0, 1, 2, then every 4 weeks; or ublituximab 150 mg IV day 1 and day 15, then 450 mg IV every 24 weeks. Anti-CD20 therapies achieve low annualized relapse rates (0.02-0.08) and reduce disability progression.
  • •Alternative high-efficacy options include natalizumab 300 mg IV every 4 weeks (requires JC virus serology to stratify PML risk; extended-interval dosing 5-8 weeks considered), cladribine 3.5 mg/kg cumulative over 2 years (oral, 1.75 mg/kg per year in two courses), and alemtuzumab 12 mg IV daily for 5 days then 3 days at month 12 (reserved for highly active RRMS after failure of other therapies due to autoimmune adverse events including thyroid disease and immune thrombocytopenia).
  • •For nonrelapsing secondary progressive MS, initiate tolebrutinib 60 mg once daily (first therapy approved based on HERCULES trial: 22.6% vs 30.7% 6-month confirmed disability progression, HR 0.69). For SPMS with continued relapses, use anti-CD20 agents or siponimod 2 mg daily (after 5-day up-titration). No neuroprotective drug has demonstrated efficacy; do not use high-dose biotin (MD1003) or simvastatin for progression.
  • •For primary progressive MS, ocrelizumab 600 mg IV every 24 weeks is the only approved DMT - reduces 12-week confirmed disability progression by 24% (NNT=16). Provide comprehensive symptomatic management including spasticity (baclofen up to 80 mg/day, tizanidine, intrathecal baclofen for refractory cases), bladder dysfunction (botulinum toxin 200-300 U intradetrusor, clean intermittent catheterization), neuropathic pain (gabapentin 300-3600 mg/day, pregabalin 150-600 mg/day), and fatigue (modafinil 100-200 mg/day, cognitive behavioral therapy, aerobic exercise ≥150 min/week).
  • •Monitor DMT safety: for anti-CD20 agents, check baseline hepatitis B serology, VZV IgG, TB, immunoglobulins; monitor CBC and Ig levels every 3-6 months. For natalizumab, check JCV serology every 6 months if negative; if positive, consider switching after 24 months. For S1P modulators (fingolimod, siponimod), baseline ECG and first-dose cardiac monitoring; for teriflunomide, monthly LFTs and blood pressure; for dimethyl fumarate, monitor lymphocyte count (discontinue if <0.5 × 10⁹/L).
  • •Switch DMT if breakthrough disease occurs (relapse, new MRI lesion, or disability progression) despite adherence. Escalate to a high-efficacy agent with a different mechanism (e.g., from fumarate to anti-CD20). For failure of anti-CD20, consider cladribine or alemtuzumab. Refer to an MS specialist center for highly aggressive or treatment-refractory cases.
  • •Do not use non-dihydropyridine calcium channel blockers (diltiazem, verapamil) - they exacerbate fatigue and have negative inotropic effects. Do not use atacicept (increases relapse rate). Avoid high-dose biotin (MD1003) - phase 3 trial negative. Do not routinely discontinue DMT without shared decision-making: in patients ≥55 years with ≥5 years no activity, discontinuation carries a 7.5% absolute increase in recurrent disease activity over 2 years (DISCOMS); continue DMT unless risks outweigh benefits. For younger patients, the risk of rebound is higher (17.8% recurrence in DOT-MS).
  • •Refer for autologous hematopoietic stem cell transplantation (aHSCT) in selected patients <50 years with disease duration <10 years who have failed high-efficacy DMT and have aggressive disease; aHSCT achieves 69.6% activity-free survival at 3 years. National MS Society recommends aHSCT in this population.
  • •During pregnancy, discontinue high-risk DMTs: stop anti-CD20 3 months before conception; stop fingolimod, cladribine, alemtuzumab before pregnancy. Interferon beta and glatiramer acetate are considered safer. For highly active MS, continuing natalizumab into the third trimester may be considered with neonatal hematologic monitoring (thrombocytopenia, anemia). Resume DMT postpartum early to reduce relapse risk.
  • •Optimize vaccination status: administer inactivated vaccines (influenza, pneumococcal, Tdap, COVID-19) ≥4-6 weeks before starting immunosuppressive DMT. Live attenuated vaccines are contraindicated during therapy. Vaccination does not increase relapse risk (COVID-19 vaccine relapse rate 1.9% within 20 days). Screen for depression (PHQ-9), cognition (annual Symbol Digit Modalities Test), and osteoporosis (DXA scan if immobile or glucocorticoid exposure).

Board Review — High Yield

  • •Clinically Isolated Syndrome (CIS), First demyelinating event (optic neuritis, transverse myelitis, brainstem syndrome); 30-50% convert to clinically definite MS within 5 years; MRI lesions and CSF oligoclonal bands increase risk.
  • •McDonald Criteria 2024, Diagnosis requires dissemination in space (≥2 of 5 regions: periventricular, juxtacortical/cortical, infratentorial, spinal cord, optic nerve) and dissemination in time (simultaneous enhancing/non-enhancing lesions or new lesions on follow-up); optic nerve and CSF κ-free light chains added.
  • •Central Vein Sign (CVS), A vein coursing through ≥40% of white matter lesions on susceptibility-weighted MRI; highly specific for MS compared to mimics (small vessel disease, migraine).
  • •Progression Independent of Relapse Activity (PIRA), Dominant mechanism of disability worsening in RRMS (78-89% of confirmed disability accumulation); driven by smoldering inflammation; early PIRA predicts 26-fold higher risk of reaching EDSS 6.0.
  • •Early High-Efficacy Therapy, Starting anti-CD20 or natalizumab within 2 years of onset reduces 10-year EDSS by ~1 point compared with escalation; 5-year EDSS change 0.3 vs 1.2 (p=0.002).
  • •Serum Neurofilament Light Chain (sNfL), Biomarker of neuroaxonal damage; elevated in active MS; predicts future relapses and disability worsening (OR 2.41; higher risk if >97.5th percentile); combined with sGFAP stratifies PIRA risk.
  • •Ocrelizumab, First drug approved for both RRMS (ARR reduction 46-47%) and PPMS (ORATORIO: 24% reduction in 12-week confirmed disability progression; NNT=16).
  • •Tolebrutinib, First therapy to show benefit in nonrelapsing SPMS (HERCULES: HR 0.69 for 6-month confirmed disability progression); brain-penetrant BTK inhibitor; requires ALT monitoring.
  • •Pregnancy and DMT, Interferon beta and glatiramer acetate are safe; anti-CD20 stopped 3 months before conception; natalizumab continuation into third trimester may be considered with neonatal monitoring; postpartum relapse risk increases significantly.
  • •DMT Discontinuation Risks, Patients ≥55 years with ≥5 years stability: 12.2% vs 4.7% disease activity over 2 years (DISCOMS, noninferiority not met); discontinuation of natalizumab or fingolimod carries high rebound risk.

Deep Dive — Evidence Details

References

  1. [1]

    Wingerchuk DM, Banwell B, Bennett JL et al.. “International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.” Neurology (2015). PMID: 26092914 ↗

    L1GUIDELINECited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment, Special Populations & Pregnancy
  2. [2]

    Montalban X, Vermersch P, Arnold DL et al.. “Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.” The Lancet. Neurology (2024). PMID: 39307151 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
  3. [3]

    Newsome SD, Krzystanek E, Selmaj KW et al.. “Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.” Neurology (2025). PMID: 40245351 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
  4. [4]

    Cerqueira JJ, Berthele A, Cree BAC et al.. “Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.” Neurology (2025). PMID: 39883906 ↗

    L2RCTCited in: Definition, Classification & Nomenclature, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
  5. [5]

    Williams MJ, Amezcua L, Cohan SL et al.. “Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.” Neurology (2024). PMID: 39018512 ↗

    L2RCTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
  6. [6]

    Hartung HP, Benedict RHB, Berger T et al.. “Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.” Neurology (2024). PMID: 39626127 ↗

    L4TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History
  7. [7]

    Kowalec K, Fitzgerald KC, Salter A et al.. “Polygenicity of Comorbid Depression in Multiple Sclerosis.” Neurology (2023). PMID: 37290970 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors
  8. [8]

    Müller J, Cagol A, Lorscheider J et al.. “Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic Review.” JAMA neurology (2023). PMID: 37782515 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  9. [9]

    Beghi E, Carpio A, Forsgren L et al.. “Recommendation for a definition of acute symptomatic seizure.” Epilepsia (2009). PMID: 19732133 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  10. [10]

    Thacker EL, Mirzaei F, Ascherio A. “Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis.” Annals of neurology (2006). PMID: 16502434 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors
  11. [11]

    Paradas C, Akman HO, Ionete C et al.. “Branching enzyme deficiency: expanding the clinical spectrum.” JAMA neurology (2014). PMID: 24248152 ↗

    L4CASE_REPORTCited in: Definition, Classification & Nomenclature, Clinical Presentation
  12. [12]

    Montalban X, Lebrun-Frénay C, Oh J et al.. “Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria.” The Lancet. Neurology (2025). PMID: 40975101 ↗

    L1REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  13. [13]

    Banwell B, Bennett JL, Marignier R et al.. “Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.” The Lancet. Neurology (2023). PMID: 36706773 ↗

    L1REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prevention, Screening & Surveillance
  14. [14]

    Petzold A, Fraser CL, Abegg M et al.. “Diagnosis and classification of optic neuritis.” The Lancet. Neurology (2022). PMID: 36179757 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment
  15. [15]

    Wattjes MP, Ciccarelli O, Reich DS et al.. “2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis.” The Lancet. Neurology (2021). PMID: 34139157 ↗

    L1REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Special Populations & Pregnancy
  16. [16]

    Barkhof F, Reich DS, Oh J et al.. “2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis.” The Lancet. Neurology (2025). PMID: 40975102 ↗

    L1REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  17. [17]

    De Meo E, Portaccio E, Giorgio A et al.. “Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis.” JAMA neurology (2021). PMID: 33393981 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care
  18. [18]

    Müller J, Sharmin S, Lorscheider J et al.. “Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.” JAMA neurology (2025). PMID: 40227706 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Prognosis & Natural History
  19. [19]

    Wolfova K, Engdahl BL, Horn J et al.. “Maternal Pregnancy Outcomes and Offspring Risk of Adult-Onset Multiple Sclerosis.” JAMA neurology (2026). PMID: 41525064 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy
  20. [20]

    Lim TR, Suthiphosuwan S, Gaitán MI et al.. “Paramagnetic Rim Lesions and Development of Clinical MS in Radiologically Isolated Syndrome.” JAMA neurology (2026). PMID: 41587044 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature
  21. [21]

    Thompson AJ, Baranzini SE, Geurts J et al.. “Multiple sclerosis.” Lancet (London, England) (2018). PMID: 29576504 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Neurorehabilitation, Symptomatic & Supportive Care
  22. [22]

    Jakimovski D, Bittner S, Zivadinov R et al.. “Multiple sclerosis.” Lancet (London, England) (2023). PMID: 37949093 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Neurorehabilitation, Symptomatic & Supportive Care
  23. [23]

    Brownlee WJ, Hardy TA, Fazekas F et al.. “Diagnosis of multiple sclerosis: progress and challenges.” Lancet (London, England) (2016). PMID: 27889190 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
  24. [24]

    Salomon JA, Vos T, Hogan DR et al.. “Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.” Lancet (London, England) (2012). PMID: 23245605 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Prevention, Screening & Surveillance
  25. [25]

    Wiles CM. “Physiotherapy and related activities in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2008). PMID: 18535020 ↗

    L5CASE_REPORTCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism (Neuroanatomic Localization), Long-term & Definitive Management (Evidence Ladder), Neurorehabilitation, Symptomatic & Supportive Care
  26. [26]

    Kvistad CE, Kråkenes T, Holmøy T et al.. “Intrathecal Mesenchymal Stem Cells in Progressive Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial (SMART-MS).” Neurology (2026). PMID: 42081777 ↗

    L1RCTCited in: Definition, Classification & Nomenclature
  27. [27]

    Siger M, Hartel M, Majos A et al.. “Revised recommendations of the Polish Medical Society of Radiology and the Polish Neurological Society for a protocol concerning routinely used magnetic resonance imaging in patients with multiple sclerosis.” Neurologia i neurochirurgia polska (2026). PMID: 41983559 ↗

    L1GUIDELINECited in: Definition, Classification & Nomenclature
  28. [28]

    Bagnato F, Sati P, Hemond CC et al.. “Imaging chronic active lesions in multiple sclerosis: a consensus statement.” Brain : a journal of neurology (2024). PMID: 38226694 ↗

    L1REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
  29. [29]

    Lebrun-Frénay C, Okuda DT, Siva A et al.. “The radiologically isolated syndrome: revised diagnostic criteria.” Brain : a journal of neurology (2023). PMID: 36864688 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prognosis & Natural History
  30. [30]

    Filippi M, Preziosa P, Banwell BL et al.. “Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines.” Brain : a journal of neurology (2019). PMID: 31209474 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  31. [31]

    Lorscheider J, Buzzard K, Jokubaitis V et al.. “Defining secondary progressive multiple sclerosis.” Brain : a journal of neurology (2016). PMID: 27401521 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature
  32. [32]

    Takai Y, Misu T, Kaneko K et al.. “Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.” Brain : a journal of neurology (2020). PMID: 32412053 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature
  33. [33]

    Filippi M, Preziosa P, Barkhof F et al.. “The ageing central nervous system in multiple sclerosis: the imaging perspective.” Brain : a journal of neurology (2024). PMID: 39045667 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  34. [34]

    Scalfari A, Traboulsee A, Oh J et al.. “Smouldering-Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions.” Annals of neurology (2024). PMID: 39051525 ↗

    L1REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Complications, Prevention, Screening & Surveillance
  35. [35]

    Polman CH, Reingold SC, Banwell B et al.. “Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.” Annals of neurology (2011). PMID: 21387374 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  36. [36]

    Brownlee WJ, Vidal-Jordana A, Shatila M et al.. “Towards a Unified Set of Diagnostic Criteria for Multiple Sclerosis.” Annals of neurology (2024). PMID: 39605172 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment
  37. [37]

    Hamzaoui M, Garcia J, Boffa G et al.. “Positron Emission Tomography with [18 F]-DPA-714 Unveils a Smoldering Component in Most Multiple Sclerosis Lesions which Drives Disease Progression.” Annals of neurology (2023). PMID: 37039158 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism (Neuroanatomic Localization)
  38. [38]

    Gaudioso CM, Mar S, Casper TC et al.. “MOG and AQP4 Antibodies among Children with Multiple Sclerosis and Controls.” Annals of neurology (2022). PMID: 36088544 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation, Special Populations & Pregnancy
  39. [39]

    Demuth S, Faddeenkov I, Paris J et al.. “PRIMUS: a precision medicine platform reusing clinical trials and registry data to support treatment selection in multiple sclerosis.” JAMIA open (2026). PMID: 42131074 ↗

    L5TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature
  40. [40]

    Wu Y, Geraldes R, Juryńczyk M et al.. “Double-negative neuromyelitis optica spectrum disorder.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 37740717 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
  41. [41]

    Hegen H, Arrambide G, Gnanapavan S et al.. “Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement.” Multiple sclerosis (Houndmills, Basingstoke, England) (2022). PMID: 36527368 ↗

    L1OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  42. [42]

    Arrambide G, Iacobaeus E, Amato MP et al.. “Aggressive multiple sclerosis (2): Treatment.” Multiple sclerosis (Houndmills, Basingstoke, England) (2020). PMID: 32530366 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature
  43. [43]

    Kister I, Kantarci OH. “Multiple Sclerosis Severity Score: Concept and applications.” Multiple sclerosis (Houndmills, Basingstoke, England) (2020). PMID: 31965877 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification
  44. [44]

    Phé V, Pakzad M, Curtis C et al.. “Urinary tract infections in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2016). PMID: 26892318 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Acute Management: Neurologic Emergencies & Attack Abortion
  45. [45]

    Santana JLS, Themoteo RM, Allioni GA et al.. “Is serum neurofilament light chain accurate enough to guide multiple sclerosis care? Diagnostic performance and optimal cutoff in a systematic review and meta-analysis.” Multiple sclerosis and related disorders (2026). PMID: 42364564 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature
  46. [46]

    Mirmosayyeb O, Panah Yazdan M, Tahmasbi Arashlow F et al.. “Optical coherence tomography measurements between multiple sclerosis and neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.” Multiple sclerosis and related disorders (2026). PMID: 42139966 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature
  47. [47]

    Vagner P, Brayner B, Rauber F et al.. “Ultra-processed food consumption and multiple sclerosis incidence: A prospective cohort study.” Clinical nutrition (Edinburgh, Scotland) (2026). PMID: 42105610 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature
  48. [48]

    Hauser SL, Bar-Or A, Comi G et al.. “Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.” The New England journal of medicine (2016). PMID: 28002679 ↗

    L1RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification, History and Evolution of Treatment
  49. [49]

    Vermersch P, Granziera C, Mao-Draayer Y et al.. “Inhibition of CD40L with Frexalimab in Multiple Sclerosis.” The New England journal of medicine (2024). PMID: 38354138 ↗

    L1RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
  50. [50]

    Hauser SL, Waubant E, Arnold DL et al.. “B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.” The New England journal of medicine (2008). PMID: 18272891 ↗

    L1RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
  51. [51]

    Montalban X, Arnold DL, Weber MS et al.. “Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.” The New England journal of medicine (2019). PMID: 31075187 ↗

    L1RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
  52. [52]

    Kappos L, Wiendl H, Selmaj K et al.. “Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.” The New England journal of medicine (2015). PMID: 26444729 ↗

    L1RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors
  53. [53]

    Kappos L, Li D, Calabresi PA et al.. “Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.” Lancet (London, England) (2011). PMID: 22047971 ↗

    L1RCTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
  54. [54]

    Conrad N, Misra S, Verbakel JY et al.. “Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.” Lancet (London, England) (2023). PMID: 37156255 ↗

    L2COHORTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  55. [55]

    Koch MW, Kaur S, Sage K et al.. “Hydroxychloroquine for Primary Progressive Multiple Sclerosis.” Annals of neurology (2021). PMID: 34590328 ↗

    L4TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prognosis & Natural History, Prevention, Screening & Surveillance
  56. [56]

    Zhornitsky S, Yong VW, Weiss S et al.. “Prolactin in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2012). PMID: 22933621 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Special Populations & Pregnancy
  57. [57]

    Steri M, Orrù V, Idda ML et al.. “Overexpression of the Cytokine BAFF and Autoimmunity Risk.” The New England journal of medicine (2017). PMID: 28445677 ↗

    L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  58. [58]

    Lucchinetti CF, Popescu BF, Bunyan RF et al.. “Inflammatory cortical demyelination in early multiple sclerosis.” The New England journal of medicine (2011). PMID: 22150037 ↗

    L4OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  59. [59]

    Srivastava R, Aslam M, Kalluri SR et al.. “Potassium channel KIR4.1 as an immune target in multiple sclerosis.” The New England journal of medicine (2012). PMID: 22784115 ↗

    L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  60. [60]

    Kuhlmann T, Moccia M, Coetzee T et al.. “Multiple sclerosis progression: time for a new mechanism-driven framework.” The Lancet. Neurology (2022). PMID: 36410373 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), History and Evolution of Treatment
  61. [61]

    Cryan JF, O'Riordan KJ, Sandhu K et al.. “The gut microbiome in neurological disorders.” The Lancet. Neurology (2019). PMID: 31753762 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors
  62. [62]

    Toosy AT, Mason DF, Miller DH. “Optic neuritis.” The Lancet. Neurology (2014). PMID: 24331795 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  63. [63]

    Wingerchuk DM, Lennon VA, Lucchinetti CF et al.. “The spectrum of neuromyelitis optica.” The Lancet. Neurology (2007). PMID: 17706564 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  64. [64]

    Aloisi F, Giovannoni G, Salvetti M. “Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy.” The Lancet. Neurology (2023). PMID: 36764322 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), History and Evolution of Treatment
  65. [65]

    Tan CS, Koralnik IJ. “Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.” The Lancet. Neurology (2010). PMID: 20298966 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  66. [66]

    Haghikia A, Schett G, Mougiakakos D. “B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases.” The Lancet. Neurology (2024). PMID: 38760099 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  67. [67]

    Pohl D, Alper G, Van Haren K et al.. “Acute disseminated encephalomyelitis: Updates on an inflammatory CNS syndrome.” Neurology (2016). PMID: 27572859 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Complications, Prognosis & Natural History, Special Populations & Pregnancy
  68. [68]

    Kluger BM, Krupp LB, Enoka RM. “Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy.” Neurology (2013). PMID: 23339207 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Neurorehabilitation, Symptomatic & Supportive Care
  69. [69]

    Schweitzer F, Laurent S, Cortese I et al.. “Progressive Multifocal Leukoencephalopathy: Pathogenesis, Diagnostic Tools, and Potential Biomarkers of Response to Therapy.” Neurology (2023). PMID: 37487750 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
  70. [70]

    Saucier L, Rossor T, Gorman MP et al.. “Diagnosis and Management of Children With Atypical Neuroinflammation.” Neurology (2025). PMID: 40184590 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Acute Management: Neurologic Emergencies & Attack Abortion, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Special Populations & Pregnancy
  71. [71]

    Absoud M, Greenberg BM, Lim M et al.. “Pediatric transverse myelitis.” Neurology (2016). PMID: 27572861 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation, Acute Management: Neurologic Emergencies & Attack Abortion, Special Populations & Pregnancy
  72. [72]

    Ciccarelli O, Barkhof F, Calabrese M et al.. “Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis.” Neurology (2024). PMID: 38889384 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification, Complications
  73. [73]

    Louis S, Carlson AK, Suresh A et al.. “Impacts of Climate Change and Air Pollution on Neurologic Health, Disease, and Practice: A Scoping Review.” Neurology (2022). PMID: 36384657 ↗

    L2REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification
  74. [74]

    Tenembaum S, Chitnis T, Ness J et al.. “Acute disseminated encephalomyelitis.” Neurology (2007). PMID: 17438235 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Special Populations & Pregnancy
  75. [75]

    Ayroza Galvão Ribeiro Gomes AB, Kulsvehagen L, Lipps P et al.. “Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients With Central Nervous System Demyelination.” JAMA neurology (2023). PMID: 37548987 ↗

    L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation
  76. [76]

    Backner Y, Kuchling J, Massarwa S et al.. “Anatomical Wiring and Functional Networking Changes in the Visual System Following Optic Neuritis.” JAMA neurology (2018). PMID: 29297053 ↗

    L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  77. [77]

    Brück W, Gold R, Lund BT et al.. “Therapeutic decisions in multiple sclerosis: moving beyond efficacy.” JAMA neurology (2013). PMID: 23921521 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  78. [78]

    Alvermann S, Hennig C, Stüve O et al.. “Immunophenotyping of cerebrospinal fluid cells in multiple sclerosis: in search of biomarkers.” JAMA neurology (2014). PMID: 24818670 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  79. [79]

    Marshall O, Lu H, Brisset JC et al.. “Impaired cerebrovascular reactivity in multiple sclerosis.” JAMA neurology (2014). PMID: 25133874 ↗

    L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  80. [80]

    Zipp F, Gold R, Wiendl H. “Identification of inflammatory neuronal injury and prevention of neuronal damage in multiple sclerosis: hope for novel therapies?” JAMA neurology (2013). PMID: 24145957 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Prevention, Screening & Surveillance
  81. [81]

    Frohman EM, Monaco MC, Remington G et al.. “JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.” JAMA neurology (2014). PMID: 24664166 ↗

    L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  82. [82]

    Zurawski J, Lassmann H, Bakshi R. “Use of Magnetic Resonance Imaging to Visualize Leptomeningeal Inflammation in Patients With Multiple Sclerosis: A Review.” JAMA neurology (2017). PMID: 27893883 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  83. [83]

    Brown RB, Traylor M, Burgess S et al.. “Do Cerebral Small Vessel Disease and Multiple Sclerosis Share Common Mechanisms of White Matter Injury?” Stroke (2019). PMID: 31221055 ↗

    L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification
  84. [84]

    Qin C, Fan WH, Liu Q et al.. “Fingolimod Protects Against Ischemic White Matter Damage by Modulating Microglia Toward M2 Polarization via STAT3 Pathway.” Stroke (2017). PMID: 29114096 ↗

    L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  85. [85]

    Vogelgesang A, Domanska G, Ruhnau J et al.. “Siponimod (BAF312) Treatment Reduces Brain Infiltration but Not Lesion Volume in Middle-Aged Mice in Experimental Stroke.” Stroke (2019). PMID: 31009359 ↗

    L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prognosis & Natural History
  86. [86]

    Zhao X, Sun G, Zhang J et al.. “Dimethyl Fumarate Protects Brain From Damage Produced by Intracerebral Hemorrhage by Mechanism Involving Nrf2.” Stroke (2015). PMID: 25977275 ↗

    L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  87. [87]

    Schett G, Mackensen A, Mougiakakos D. “CAR T-cell therapy in autoimmune diseases.” Lancet (London, England) (2023). PMID: 37748491 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  88. [88]

    McGinley MP, Cohen JA. “Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.” Lancet (London, England) (2021). PMID: 34175020 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  89. [89]

    Vincent A, Crino PB. “Systemic and neurologic autoimmune disorders associated with seizures or epilepsy.” Epilepsia (2011). PMID: 21542840 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Clinical Presentation
  90. [90]

    Lublin FD, Häring DA, Ganjgahi H et al.. “How patients with multiple sclerosis acquire disability.” Brain : a journal of neurology (2022). PMID: 35104840 ↗

    L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
  91. [91]

    Lin J, Zhou J, Xu Y. “Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis.” Brain : a journal of neurology (2023). PMID: 36864689 ↗

    L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Prognosis & Natural History, Prevention, Screening & Surveillance
  92. [92]

    Belbasis L, Morris S, van Duijn C et al.. “Mendelian randomization identifies proteins involved in neurodegenerative diseases.” Brain : a journal of neurology (2025). PMID: 40037332 ↗

    L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification
  93. [93]

    Carotenuto A, Cacciaguerra L, Pagani E et al.. “Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability.” Brain : a journal of neurology (2022). PMID: 34919648 ↗

    L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  94. [94]

    Furlan R, Schaedelin S, Frederiksen JL et al.. “Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.” Brain : a journal of neurology (2026). PMID: 40988129 ↗

    L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification
  95. [95]

    Sun J, Guo M, Chai L et al.. “Distinct virtual histology of grey matter atrophy in four neuroinflammatory diseases.” Brain : a journal of neurology (2024). PMID: 38703370 ↗

    L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  96. [96]

    Huang J, Tengvall K, Lima IB et al.. “Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis.” Brain : a journal of neurology (2024). PMID: 38630618 ↗

    L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, History and Evolution of Treatment
  97. [97]

    Herranz E, Treaba CA, Barletta VT et al.. “Characterization of cortico-meningeal translocator protein expression in multiple sclerosis.” Brain : a journal of neurology (2024). PMID: 38289855 ↗

    L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Severity, Staging & Risk Stratification
  98. [98]

    Comi G, Bar-Or A, Lassmann H et al.. “Role of B Cells in Multiple Sclerosis and Related Disorders.” Annals of neurology (2020). PMID: 33091175 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  99. [99]

    Greenfield AL, Hauser SL. “B-cell Therapy for Multiple Sclerosis: Entering an era.” Annals of neurology (2018). PMID: 29244240 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  100. [100]

    Papadopoulos D, Magliozzi R, Bandiera S et al.. “Accelerated Cellular Senescence in Progressive Multiple Sclerosis: A Histopathological Study.” Annals of neurology (2025). PMID: 39891488 ↗

    L3OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  101. [101]

    Murphy OC, Sotirchos ES, Kalaitzidis G et al.. “Trans-Synaptic Degeneration Following Acute Optic Neuritis in Multiple Sclerosis.” Annals of neurology (2022). PMID: 36218157 ↗

    L2OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  102. [102]

    Wollebo HS, White MK, Gordon J et al.. “Persistence and pathogenesis of the neurotropic polyomavirus JC.” Annals of neurology (2015). PMID: 25623836 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  103. [103]

    Cohen JA, Chun J. “Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.” Annals of neurology (2011). PMID: 21520239 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Complications
  104. [104]

    Zhang Y, Atkinson J, Burd CE et al.. “Biological aging in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 37877740 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  105. [105]

    Bhargava P, Calabresi PA. “Metabolomics in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2016). PMID: 26754801 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prognosis & Natural History
  106. [106]

    Soelberg Sorensen P, Giovannoni G, Montalban X et al.. “The Multiple Sclerosis Care Unit.” Multiple sclerosis (Houndmills, Basingstoke, England) (2018). PMID: 30351211 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Neurorehabilitation, Symptomatic & Supportive Care
  107. [107]

    Bergsland N, Dwyer MG, Zivadinov R. “Imaging the Choroid Plexus.” Multiple sclerosis (Houndmills, Basingstoke, England) (2024). PMID: 39658900 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  108. [108]

    Tur C, Montalban X. “Progressive MS trials: Lessons learned.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 29041872 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  109. [109]

    Bhargava P, Anthony DC. “Metabolomics in multiple sclerosis disease course and progression.” Multiple sclerosis (Houndmills, Basingstoke, England) (2020). PMID: 31965880 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  110. [110]

    Koks F, Reubens F, van der Zee H et al.. “The dual role of mTOR in multiple sclerosis pathophysiology: a systematic review.” Journal of neurology (2026). PMID: 42390760 ↗

    L5SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  111. [111]

    Bartczak J, Gronowski P, Małek M et al.. “Experimental Therapies in Multiple Sclerosis: Epstein-Barr Virus and Potential EBV-Related Therapeutic Strategies-A Systematic Review.” Journal of clinical medicine (2026). PMID: 42278964 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prevention, Screening & Surveillance
  112. [112]

    Abbasi H, Ahmadi B, Sherafati N et al.. “The Association Between Serum α-Tocopherol and Pathogenesis of Multiple Sclerosis: A Systematic Review and Meta-Analysis of Case-Control Studies.” BioMed research international (2026). PMID: 42421296 ↗

    L3SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Prevention, Screening & Surveillance
  113. [113]

    Sedighi B, Jafari S, Rahmati S et al.. “The Association between Dairy Consumption and the Risk of Developing Multiple Sclerosis: A Systematic Review and Meta-Analysis.” Iranian journal of public health (2025). PMID: 42428733 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  114. [114]

    Mirchi A, Vossough A, Liu GT et al.. “Pearls & Oy-sters: Radiologic Lag in Pediatric-Onset Multiple Sclerosis.” Neurology (2026). PMID: 42320011 ↗

    L4CASE_REPORTCited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  115. [115]

    Bernaerts E, De Visscher A, Vanherle S et al.. “Matrix metalloprotease-9 modulates microglial/macrophage responses in murine brain demyelination.” Acta neuropathologica communications (2026). PMID: 42432780 ↗

    L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  116. [116]

    Lu K, Lu Y, Tang R et al.. “Mechanisms of autophagy-lysosome pathway impairment in Alzheimer's disease.” Journal of Alzheimer's disease : JAD (2026). PMID: 42429504 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization)
  117. [117]

    Suhadolc A, Horvat S, Kos J et al.. “Glial Cysteine Cathepsins: From Homeostasis to Neurodegeneration.” Cellular and molecular neurobiology (2026). PMID: 42426293 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Clinical Presentation
  118. [118]

    Zesiewicz TA, Wilmot G, Kuo SH et al.. “Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.” Neurology (2018). PMID: 29440566 ↗

    L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care
  119. [119]

    Torkildsen Ø, Brustad HK, Høgestøl EA et al.. “Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.” The New England journal of medicine (2026). PMID: 42384870 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment, Prognosis & Natural History
  120. [120]

    O'Connor P, Wolinsky JS, Confavreux C et al.. “Randomized trial of oral teriflunomide for relapsing multiple sclerosis.” The New England journal of medicine (2011). PMID: 21991951 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  121. [121]

    Fox RJ, Miller DH, Phillips JT et al.. “Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.” The New England journal of medicine (2012). PMID: 22992072 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors
  122. [122]

    Kappos L, Fox RJ, Burcklen M et al.. “Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.” JAMA neurology (2021). PMID: 33779698 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  123. [123]

    Cree BAC, Fox E, Hartung HP et al.. “Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.” JAMA neurology (2026). PMID: 41697690 ↗

    L2RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
  124. [124]

    Chen Y, Bord E, Tompkins T et al.. “Asymptomatic reactivation of JC virus in patients treated with natalizumab.” The New England journal of medicine (2009). PMID: 19741227 ↗

    L4TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  125. [125]

    Belbasis L, Bellou V, Evangelou E et al.. “Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses.” The Lancet. Neurology (2015). PMID: 25662901 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  126. [126]

    Butzkueven H, Ponsonby AL, Stein MS et al.. “Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome.” Brain : a journal of neurology (2024). PMID: 38085047 ↗

    L2RCTCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prognosis & Natural History
  127. [127]

    Feigin VL, Vos T, Alahdab F et al.. “Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study.” JAMA neurology (2021). PMID: 33136137 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications, Prognosis & Natural History
  128. [128]

    Chen H, Kwong JC, Copes R et al.. “Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study.” Lancet (London, England) (2017). PMID: 28063597 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors
  129. [129]

    Traboulsee AL, Knox KB, Machan L et al.. “Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: a blinded, case-control study.” Lancet (London, England) (2013). PMID: 24119384 ↗

    L3CASE_CONTROLCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  130. [130]

    Munk Nielsen N, Corn G, Frisch M et al.. “Multiple sclerosis among first- and second-generation immigrants in Denmark: a population-based cohort study.” Brain : a journal of neurology (2019). PMID: 31081503 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors
  131. [131]

    Benedict RHB, Amato MP, DeLuca J et al.. “Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues.” The Lancet. Neurology (2020). PMID: 32949546 ↗

    L5CASE_REPORTCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Neurologic Emergencies & Attack Abortion
  132. [132]

    Rahimov F, Jacobs BM, Lee JS et al.. “Common Diseases in Clinical Cohorts - Not Always What They Seem.” The New England journal of medicine (2025). PMID: 41124632 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  133. [133]

    Hafler DA, Compston A, Sawcer S et al.. “Risk alleles for multiple sclerosis identified by a genomewide study.” The New England journal of medicine (2007). PMID: 17660530 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors
  134. [134]

    Bloomgren G, Richman S, Hotermans C et al.. “Risk of natalizumab-associated progressive multifocal leukoencephalopathy.” The New England journal of medicine (2012). PMID: 22591293 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  135. [135]

    Lebrun-Frenay C, Kantarci O, Siva A et al.. “Radiologically isolated syndrome.” The Lancet. Neurology (2023). PMID: 37839432 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
  136. [136]

    . “Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.” The Lancet. Neurology (2019). PMID: 30879893 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Neurorehabilitation, Symptomatic & Supportive Care, Complications
  137. [137]

    . “Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.” The Lancet. Neurology (2019). PMID: 30679040 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  138. [138]

    Miller DH, Chard DT, Ciccarelli O. “Clinically isolated syndromes.” The Lancet. Neurology (2012). PMID: 22265211 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
  139. [139]

    Cruccu G, Finnerup NB, Jensen TS et al.. “Trigeminal neuralgia: New classification and diagnostic grading for practice and research.” Neurology (2016). PMID: 27306631 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Neurorehabilitation, Symptomatic & Supportive Care
  140. [140]

    Hauser SL, Kappos L, Montalban X et al.. “Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.” Neurology (2021). PMID: 34475123 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
  141. [141]

    Zhang C, Liu W, Wang L et al.. “Prevalence and Burden of Multiple Sclerosis in China, 1990-2019: Findings From the Global Burden of Disease Study 2019.” Neurology (2024). PMID: 38759127 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications
  142. [142]

    Wallin MT, Culpepper WJ, Campbell JD et al.. “The prevalence of MS in the United States: A population-based estimate using health claims data.” Neurology (2019). PMID: 30770430 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  143. [143]

    Luna G, Alping P, Burman J et al.. “Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.” JAMA neurology (2020). PMID: 31589278 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  144. [144]

    Fissolo N, Schaedelin S, Villar LM et al.. “Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome.” JAMA neurology (2025). PMID: 40455494 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  145. [145]

    Iaffaldano P, Portaccio E, Lucisano G et al.. “Multiple Sclerosis Progression and Relapse Activity in Children.” JAMA neurology (2024). PMID: 38010712 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Special Populations & Pregnancy
  146. [146]

    Koch M, Uyttenboogaart M, Polman S et al.. “Seizures in multiple sclerosis.” Epilepsia (2008). PMID: 18336559 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Prognosis & Natural History
  147. [147]

    Li EC, Zheng Y, Cai MT et al.. “Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease.” Epilepsia (2022). PMID: 35652436 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  148. [148]

    Håkansson S, Karlander M, Larsson D et al.. “Potential for improved retention rate by personalized antiseizure medication selection: A register-based analysis.” Epilepsia (2021). PMID: 34245010 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
  149. [149]

    Petzold A, Chua SYL, Khawaja AP et al.. “Retinal asymmetry in multiple sclerosis.” Brain : a journal of neurology (2021). PMID: 33253371 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prevention, Screening & Surveillance
  150. [150]

    Jacobs BM, Vandebergh M, Maltby VE et al.. “Interplay between genetic and environmental risk factors in multiple sclerosis: what have we learned?” Brain : a journal of neurology (2026). PMID: 41889330 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors
  151. [151]

    Akada M, Hata M, Miyake M et al.. “Natural experiment on neuroinflammatory disease incidence and infection links pre- and post-COVID-19.” Brain : a journal of neurology (2026). PMID: 41359492 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  152. [152]

    Disanto G, Barro C, Benkert P et al.. “Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.” Annals of neurology (2017). PMID: 28512753 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  153. [153]

    Brahic M. “Multiple sclerosis and viruses.” Annals of neurology (2010). PMID: 20582990 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors
  154. [154]

    Dal Bianco A, Bradl M, Frischer J et al.. “Multiple sclerosis and Alzheimer's disease.” Annals of neurology (2008). PMID: 17924575 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors
  155. [155]

    Manouchehrinia A, Fitzgerald KC, Salter A et al.. “Depression Polygenicity and Disease Activity and Disability Worsening in Multiple Sclerosis.” Annals of neurology (2025). PMID: 40772555 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  156. [156]

    Ascherio A, Munger KL. “Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors.” Annals of neurology (2007). PMID: 17492755 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  157. [157]

    Dobson R, Jitlal M, Marshall CR et al.. “Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk.” Annals of neurology (2020). PMID: 31975487 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors
  158. [158]

    Ascherio A, Munger KL. “Environmental risk factors for multiple sclerosis. Part I: the role of infection.” Annals of neurology (2007). PMID: 17444504 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  159. [159]

    Walton C, King R, Rechtman L et al.. “Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.” Multiple sclerosis (Houndmills, Basingstoke, England) (2020). PMID: 33174475 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
  160. [160]

    Hearn AP, Silber E. “Osteoporosis in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2010). PMID: 20551086 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Complications, Prognosis & Natural History, Prevention, Screening & Surveillance
  161. [161]

    Feinstein A, Pavisian B. “Multiple sclerosis and suicide.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 28327056 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications, Prevention, Screening & Surveillance
  162. [162]

    Feinstein A. “Multiple sclerosis and depression.” Multiple sclerosis (Houndmills, Basingstoke, England) (2011). PMID: 22058085 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management (Evidence Ladder), Neurorehabilitation, Symptomatic & Supportive Care, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance
  163. [163]

    Dobson R, Ramagopalan S, Giovannoni G. “Bone health and multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2012). PMID: 22740489 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications, Prognosis & Natural History
  164. [164]

    Freedman DE, Krysko KM, Feinstein A. “Intimate partner violence and multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 37732567 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors
  165. [165]

    Marrodan M, Alessandro L, Farez MF et al.. “The role of infections in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2019). PMID: 30638421 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  166. [166]

    . “Corrigendum.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 28608736 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors
  167. [167]

    White E, Adanijo A, Papiernik-Berkhauer P et al.. “Effectiveness of non-pharmacological treatments for sexual difficulties in adults with multiple sclerosis: a systematic review and meta-analysis.” Sexual medicine reviews (2026). PMID: 42407255 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Neurorehabilitation, Symptomatic & Supportive Care
  168. [168]

    Hammadeh BM, Sameer S, Alnajjar M et al.. “Efficacy and safety of extended-interval dosing of natalizumab in multiple sclerosis: a systematic review and meta-analysis with subgroup evaluation.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42393408 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
  169. [169]

    Horsdal HT, Heitmann B, Boelt SG et al.. “Neonatal vitamin D levels and autoimmune disorders: a Danish population-based cohort study.” European journal of epidemiology (2026). PMID: 42418142 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors
  170. [170]

    Maunula A, Laakso SM, Viitala M et al.. “Cancer risk and mortality in patients with multiple sclerosis in Finland: a retrospective population-based cohort study.” Journal of neurology, neurosurgery, and psychiatry (2026). PMID: 42386505 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Complications
  171. [171]

    Paybast S, Asl Fallah E, Sahraian MA et al.. “Pregnancy outcomes in patients with multiple sclerosis with or without exposure to disease-modifying treatment: A retrospective cohort study on Iranian population.” Multiple sclerosis and related disorders (2026). PMID: 42322960 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Special Populations & Pregnancy
  172. [172]

    Althobaiti AH, Elrashidy MA, Alabdulhadi AS et al.. “Anti-JCV antibody seroprevalence and testing practices in multiple sclerosis patients considered for natalizumab therapy: a retrospective study from King Saud Medical City, Riyadh, Saudi Arabia.” Multiple sclerosis and related disorders (2026). PMID: 42287857 ↗

    L4COHORTCited in: Epidemiology, Etiology & Risk Factors, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  173. [173]

    Galus W, Winder M, Owczarek AJ et al.. “Smoking, Comorbidities, and Low Sun Exposure Are Associated with Clinical and Radiological Outcomes in Patients with Multiple Sclerosis-A Four-Year Observational Cohort Study.” Journal of clinical medicine (2026). PMID: 42279131 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors
  174. [174]

    Cohen JA, Reingold SC, Polman CH et al.. “Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.” The Lancet. Neurology (2012). PMID: 22516081 ↗

    L5TRIAL_NONRANDOMCited in: Clinical Presentation, Neurorehabilitation, Symptomatic & Supportive Care
  175. [175]

    Filippi M, Preziosa P, Meani A et al.. “Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study.” The Lancet. Neurology (2017). PMID: 29275979 ↗

    L2COHORTCited in: Clinical Presentation
  176. [176]

    Otero-Romero S, Sastre-Garriga J, Comi G et al.. “Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.” Multiple sclerosis (Houndmills, Basingstoke, England) (2016). PMID: 27207462 ↗

    L1SR_OBSCited in: Clinical Presentation
  177. [177]

    Yousry TA, Major EO, Ryschkewitsch C et al.. “Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.” The New England journal of medicine (2006). PMID: 16510746 ↗

    L4OTHERCited in: Clinical Presentation, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  178. [178]

    Renoux C, Vukusic S, Mikaeloff Y et al.. “Natural history of multiple sclerosis with childhood onset.” The New England journal of medicine (2007). PMID: 17582070 ↗

    L2OTHERCited in: Clinical Presentation
  179. [179]

    Thompson AJ, Banwell BL, Barkhof F et al.. “Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.” The Lancet. Neurology (2017). PMID: 29275977 ↗

    L1REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  180. [180]

    Miller DH, Leary SM. “Primary-progressive multiple sclerosis.” The Lancet. Neurology (2007). PMID: 17884680 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  181. [181]

    Cortese R, Prados Carrasco F, Tur C et al.. “Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.” Neurology (2022). PMID: 36192175 ↗

    L3OTHERCited in: Clinical Presentation
  182. [182]

    Cacciaguerra L, Morris P, Tobin WO et al.. “Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.” Neurology (2023). PMID: 36690455 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  183. [183]

    Carta S, Cobo Calvo Á, Armangué T et al.. “Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study.” Neurology (2022). PMID: 36526426 ↗

    L3OTHERCited in: Clinical Presentation, Severity, Staging & Risk Stratification
  184. [184]

    Waldman A, Ness J, Pohl D et al.. “Pediatric multiple sclerosis: Clinical features and outcome.” Neurology (2016). PMID: 27572865 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Neurorehabilitation, Symptomatic & Supportive Care
  185. [185]

    Dubey D, Pittock SJ, Krecke KN et al.. “Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.” JAMA neurology (2019). PMID: 30575890 ↗

    L4OTHERCited in: Clinical Presentation
  186. [186]

    Hua LH, Solomon AJ, Tenembaum S et al.. “Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations: A Review.” JAMA neurology (2024). PMID: 39283621 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  187. [187]

    Ayrignac X, Carra-Dallière C, Marelli C et al.. “Adult-Onset Genetic Central Nervous System Disorders Masquerading as Acquired Neuroinflammatory Disorders: A Review.” JAMA neurology (2022). PMID: 35969413 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  188. [188]

    Andorrà M, Alba-Arbalat S, Camos-Carreras A et al.. “Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis.” JAMA neurology (2020). PMID: 31566686 ↗

    L2OTHERCited in: Clinical Presentation
  189. [189]

    Meltzer E, Sguigna PV, Subei A et al.. “Retinal Architecture and Melanopsin-Mediated Pupillary Response Characteristics: A Putative Pathophysiologic Signature for the Retino-Hypothalamic Tract in Multiple Sclerosis.” JAMA neurology (2017). PMID: 28135360 ↗

    L3OTHERCited in: Clinical Presentation
  190. [190]

    Giovannoni G, James L, Adeniran AA et al.. “The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis.” Brain : a journal of neurology (2025). PMID: 40327539 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  191. [191]

    Cortese R, Battaglini M, Prados F et al.. “Clinical and MRI measures to identify non-acute MOG-antibody disease in adults.” Brain : a journal of neurology (2023). PMID: 36515653 ↗

    L3OTHERCited in: Clinical Presentation
  192. [192]

    Jurynczyk M, Messina S, Woodhall MR et al.. “Clinical presentation and prognosis in MOG-antibody disease: a UK study.” Brain : a journal of neurology (2017). PMID: 29136091 ↗

    L2OTHERCited in: Clinical Presentation
  193. [193]

    Longoni G, Brown RA, MomayyezSiahkal P et al.. “White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders.” Brain : a journal of neurology (2017). PMID: 28334875 ↗

    L2OTHERCited in: Clinical Presentation
  194. [194]

    Jokubaitis VG, Campagna MP, Ibrahim O et al.. “Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity.” Brain : a journal of neurology (2023). PMID: 36448302 ↗

    L2OTHERCited in: Clinical Presentation
  195. [195]

    Haider L, Prados F, Chung K et al.. “Cortical involvement determines impairment 30 years after a clinically isolated syndrome.” Brain : a journal of neurology (2021). PMID: 33880511 ↗

    L2OTHERCited in: Clinical Presentation
  196. [196]

    Zrzavy T, Hametner S, Wimmer I et al.. “Loss of 'homeostatic' microglia and patterns of their activation in active multiple sclerosis.” Brain : a journal of neurology (2017). PMID: 28541408 ↗

    L4OTHERCited in: Clinical Presentation
  197. [197]

    Cox LM, Maghzi AH, Liu S et al.. “Gut Microbiome in Progressive Multiple Sclerosis.” Annals of neurology (2021). PMID: 33876477 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Neurorehabilitation, Symptomatic & Supportive Care
  198. [198]

    Marrodan M, Calandri IL, Bocancea DI et al.. “Diagnostic MRI Score to Differentiate Susac Syndrome from Primary Angiitis of the Central Nervous System and Multiple Sclerosis.” Annals of neurology (2024). PMID: 39056308 ↗

    L3OTHERCited in: Clinical Presentation
  199. [199]

    Zrzavy T, Endmayr V, Bauer J et al.. “Neuropathological Variability within a Spectrum of NMDAR-Encephalitis.” Annals of neurology (2021). PMID: 34562035 ↗

    L4OTHERCited in: Clinical Presentation
  200. [200]

    Knowles S, Middleton R, Cooze B et al.. “Comparing the Pathology, Clinical, and Demographic Characteristics of Younger and Older-Onset Multiple Sclerosis.” Annals of neurology (2023). PMID: 38061895 ↗

    L2OTHERCited in: Clinical Presentation
  201. [201]

    Fisniku LK, Chard DT, Jackson JS et al.. “Gray matter atrophy is related to long-term disability in multiple sclerosis.” Annals of neurology (2008). PMID: 18570297 ↗

    L2OTHERCited in: Clinical Presentation
  202. [202]

    Bose G, Healy BC, Lokhande HA et al.. “Early Predictors of Clinical and MRI Outcomes Using Least Absolute Shrinkage and Selection Operator (LASSO) in Multiple Sclerosis.” Annals of neurology (2022). PMID: 35429009 ↗

    L2OTHERCited in: Clinical Presentation
  203. [203]

    Tremlett H, Waubant E. “Gut microbiome and pediatric multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2018). PMID: 29307301 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Special Populations & Pregnancy
  204. [204]

    Amezcua L, McCauley JL. “Race and ethnicity on MS presentation and disease course.” Multiple sclerosis (Houndmills, Basingstoke, England) (2020). PMID: 31965878 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  205. [205]

    Leibovitch EC, Jacobson S. “Viruses in chronic progressive neurologic disease.” Multiple sclerosis (Houndmills, Basingstoke, England) (2018). PMID: 29307291 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  206. [206]

    Kim TB, Lee JY, Brinker A et al.. “Anaphylaxis and glatiramer acetate.” Multiple sclerosis (Houndmills, Basingstoke, England) (2025). PMID: 41139841 ↗

    L4OTHERCited in: Clinical Presentation
  207. [207]

    Berger JR, Pocoski J, Preblick R et al.. “Fatigue heralding multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2013). PMID: 23439577 ↗

    L3OTHERCited in: Clinical Presentation
  208. [208]

    Bennett JL, de Seze J, Lana-Peixoto M et al.. “Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography.” Multiple sclerosis (Houndmills, Basingstoke, England) (2015). PMID: 25662342 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  209. [209]

    Huang Y, Li W, Wang Y et al.. “Clinical characteristics, diagnosis, treatment, and prognosis of rituximab-induced serum sickness: a retrospective analysis of 39 reported cases.” Frontiers in immunology (2026). PMID: 42051532 ↗

    L4SR_OBSCited in: Clinical Presentation
  210. [210]

    Chen H, Cortese M, Flores-Torres MH et al.. “Comorbidities and lifestyle changes as predictors of the multiple sclerosis prodrome: A prospective cohort study.” Multiple sclerosis (Houndmills, Basingstoke, England) (2026). PMID: 42267700 ↗

    L2COHORTCited in: Clinical Presentation
  211. [211]

    Çerçi Kubur Ç, Cengiz Özyurt B, Orak SA et al.. “Clinical, Radiological, and Prognostic Features of Pediatric Clinically Isolated Syndrome and Risk of Conversion to Multiple Sclerosis: A Single-center Cohort Study.” Neuropediatrics (2026). PMID: 42263695 ↗

    L2COHORTCited in: Clinical Presentation
  212. [212]

    Akkawi N, Mohamed EH, Shatila A. “Ravulizumab for relapse prevention in AQP4-IgG-positive neuromyelitis optica spectrum disorder: a 2-year follow-up case report.” Frontiers in medicine (2026). PMID: 42369157 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Acute Management: Neurologic Emergencies & Attack Abortion
  213. [213]

    Mahfouz S, Loutfi T, Jreige W et al.. “Suspected HSV vs. demyelinating transverse myelitis in patient on TNF alpha inhibitor: a case report.” Frontiers in medicine (2026). PMID: 42180712 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  214. [214]

    Barbiero A, Lilleri D, d'Angelo P et al.. “Possible role of hyperimmunoglobulin in reducing the risk of maternal-fetal transmission of cytomegalovirus in the valacyclovir era: a case series.” Archives of gynecology and obstetrics (2026). PMID: 42045416 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  215. [215]

    Hauser SL, Bar-Or A, Cohen JA et al.. “Ofatumumab versus Teriflunomide in Multiple Sclerosis.” The New England journal of medicine (2020). PMID: 32757523 ↗

    L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment
  216. [216]

    Montalban X, Hauser SL, Kappos L et al.. “Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.” The New England journal of medicine (2016). PMID: 28002688 ↗

    L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
  217. [217]

    Steinman L, Fox E, Hartung HP et al.. “Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.” The New England journal of medicine (2022). PMID: 36001711 ↗

    L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment
  218. [218]

    Polman CH, O'Connor PW, Havrdova E et al.. “A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.” The New England journal of medicine (2006). PMID: 16510744 ↗

    L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, History and Evolution of Treatment
  219. [219]

    Giovannoni G, Comi G, Cook S et al.. “A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.” The New England journal of medicine (2010). PMID: 20089960 ↗

    L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
  220. [220]

    Chitnis T, Arnold DL, Banwell B et al.. “Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.” The New England journal of medicine (2018). PMID: 30207920 ↗

    L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Special Populations & Pregnancy
  221. [221]

    Lebrun-Frénay C, Siva A, Sormani MP et al.. “Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial.” JAMA neurology (2023). PMID: 37603328 ↗

    L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment, Special Populations & Pregnancy
  222. [222]

    Coerver EME, Fung WH, de Beukelaar J et al.. “Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial.” JAMA neurology (2025). PMID: 39652340 ↗

    L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Complications, Prognosis & Natural History
  223. [223]

    Green AJ, Gelfand JM, Cree BA et al.. “Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.” Lancet (London, England) (2017). PMID: 29029896 ↗

    L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Prognosis & Natural History
  224. [224]

    Chataway J, Williams T, Blackstone J et al.. “Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2025). PMID: 41045938 ↗

    L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
  225. [225]

    Atkins HL, Bowman M, Allan D et al.. “Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.” Lancet (London, England) (2016). PMID: 27291994 ↗

    L4RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Complications, Prognosis & Natural History
  226. [226]

    Lublin F, Miller DH, Freedman MS et al.. “Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2016). PMID: 26827074 ↗

    L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, History and Evolution of Treatment
  227. [227]

    Kappos L, Freedman MS, Polman CH et al.. “Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.” Lancet (London, England) (2007). PMID: 17679016 ↗

    L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  228. [228]

    Petzold A, Balcer LJ, Calabresi PA et al.. “Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.” The Lancet. Neurology (2017). PMID: 28920886 ↗

    L1SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  229. [229]

    Hawker K, O'Connor P, Freedman MS et al.. “Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.” Annals of neurology (2009). PMID: 19847908 ↗

    L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
  230. [230]

    Cotter J, Firth J, Enzinger C et al.. “Social cognition in multiple sclerosis: A systematic review and meta-analysis.” Neurology (2016). PMID: 27655736 ↗

    L1SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Neurorehabilitation, Symptomatic & Supportive Care
  231. [231]

    Bridel C, van Wieringen WN, Zetterberg H et al.. “Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.” JAMA neurology (2019). PMID: 31206160 ↗

    L1SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prognosis & Natural History
  232. [232]

    Hegen H, Walde J, Berek K et al.. “Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2022). PMID: 36453167 ↗

    L1SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  233. [233]

    Bennett JL, Costello F, Chen JJ et al.. “Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment.” The Lancet. Neurology (2022). PMID: 36155661 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
  234. [234]

    Solomon AJ, Arrambide G, Brownlee WJ et al.. “Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.” The Lancet. Neurology (2023). PMID: 37479377 ↗

    L1REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  235. [235]

    Cree BAC, Arnold DL, Chataway J et al.. “Secondary Progressive Multiple Sclerosis: New Insights.” Neurology (2021). PMID: 34088878 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  236. [236]

    Vidal-Jordana A, Rovira A, Calderon W et al.. “Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study.” Neurology (2023). PMID: 38165378 ↗

    L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  237. [237]

    Roos I, Hughes S, McDonnell G et al.. “Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.” JAMA neurology (2023). PMID: 37307006 ↗

    L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
  238. [238]

    Absinta M, Sati P, Masuzzo F et al.. “Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo.” JAMA neurology (2019). PMID: 31403674 ↗

    L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
  239. [239]

    Salter A, Lancia S, Kowalec K et al.. “Comorbidity and Disease Activity in Multiple Sclerosis.” JAMA neurology (2024). PMID: 39291661 ↗

    L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prevention, Screening & Surveillance
  240. [240]

    Jouvenot G, Courbon G, Lefort M et al.. “High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.” JAMA neurology (2024). PMID: 38526462 ↗

    L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder)
  241. [241]

    Vietzen H, Kühner LM, Berger SM et al.. “Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory Diseases.” JAMA neurology (2026). PMID: 41801194 ↗

    L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  242. [242]

    Bobinger T, Manaenko A, Burkardt P et al.. “Siponimod (BAF-312) Attenuates Perihemorrhagic Edema And Improves Survival in Experimental Intracerebral Hemorrhage.” Stroke (2019). PMID: 31558140 ↗

    L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
  243. [243]

    Compston A, Coles A. “Multiple sclerosis.” Lancet (London, England) (2008). PMID: 18970977 ↗

    L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  244. [244]

    Correale J, Gaitán MI, Ysrraelit MC et al.. “Progressive multiple sclerosis: from pathogenic mechanisms to treatment.” Brain : a journal of neurology (2017). PMID: 27794524 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  245. [245]

    Matsumoto Y, Kaneko K, Takahashi T et al.. “Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.” Brain : a journal of neurology (2023). PMID: 37061817 ↗

    L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  246. [246]

    Balcer LJ, Miller DH, Reingold SC et al.. “Vision and vision-related outcome measures in multiple sclerosis.” Brain : a journal of neurology (2014). PMID: 25433914 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care
  247. [247]

    Granziera C, Wuerfel J, Barkhof F et al.. “Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis.” Brain : a journal of neurology (2021). PMID: 33970206 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  248. [248]

    Bigotte M, Groh AMR, Afanasiev E et al.. “Cerebrospinal fluid-driven ependymal motile cilia defects are implicated in multiple sclerosis.” Brain : a journal of neurology (2025). PMID: 41277219 ↗

    L3OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment
  249. [249]

    Willard C, Puglisi L, Ravi D et al.. “Combined magnetic resonance imaging and serum analysis reveals distinct multiple sclerosis types.” Brain : a journal of neurology (2025). PMID: 41325776 ↗

    L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  250. [250]

    Mangioris G, Pittock SJ, Yang B et al.. “Cerebrospinal Fluid Cytokine and Chemokine Profiles in Central Nervous System Sarcoidosis: Diagnostic and Immunopathologic Insights.” Annals of neurology (2024). PMID: 39031103 ↗

    L3OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  251. [251]

    Androdias G, Bernard E, Biotti D et al.. “Multiple sclerosis broke my heart.” Annals of neurology (2017). PMID: 28437859 ↗

    L4OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Acute Management: Neurologic Emergencies & Attack Abortion
  252. [252]

    Heming M, Börsch AL, Melnik S et al.. “Atlas of Cerebrospinal Fluid Immune Cells Across Neurological Diseases.” Annals of neurology (2024). PMID: 39665159 ↗

    L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  253. [253]

    Bove R, Langdon D, Maciejowski M et al.. “Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study.” Journal of neurology (2026). PMID: 42371147 ↗

    L4TRIAL_NONRANDOMCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
  254. [254]

    Penner IK, Raselli C, Stöcklin M et al.. “The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue.” Multiple sclerosis (Houndmills, Basingstoke, England) (2009). PMID: 19995840 ↗

    L3OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification
  255. [255]

    . “Corrigendum.” Multiple sclerosis (Houndmills, Basingstoke, England) (2010). PMID: 20123935 ↗

    L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  256. [256]

    Tackley G, Kuker W, Palace J. “Magnetic resonance imaging in neuromyelitis optica.” Multiple sclerosis (Houndmills, Basingstoke, England) (2014). PMID: 24829291 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  257. [257]

    Hochstetler A, Lehtinen MK. “Choroid Plexus as a Mediator of CNS Inflammation in Multiple Sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2024). PMID: 39503321 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  258. [258]

    Prineas JW, Parratt JDE. “Multiple sclerosis: Serum anti-CNS autoantibodies.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 28548612 ↗

    L3OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  259. [259]

    Moreno-Bernardino CJ, Treviño-Frenk I, Ortiz-Maldonado JF et al.. “Predictors of early response to cladribine in mexican patients with multiple sclerosis: A real world multicenter retrospective cohort study.” Multiple sclerosis and related disorders (2026). PMID: 42364569 ↗

    L2COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  260. [260]

    Maghbooli Z, Nasir E, Mahdavinasab F et al.. “The HLA paradox across populations in multiple sclerosis progression: a systematic review.” BMC neurology (2026). PMID: 42343278 ↗

    L1SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  261. [261]

    Rościszewska-Żukowska I, Popiel M, Perenc A et al.. “Testosterone in Relapsing-Remitting Multiple Sclerosis: A Case-Control Study.” Journal of clinical medicine (2026). PMID: 42355569 ↗

    L3CASE_CONTROLCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  262. [262]

    Abdulridha GAO, Fadhel AS, Al-Kinany SQ et al.. “Serum IDO1 and β-catenin levels in patients with multiple sclerosis with and without atherosclerosis: A case-control study.” Journal of neuroimmunology (2026). PMID: 42361476 ↗

    L3CASE_CONTROLCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  263. [263]

    Wyse C, Roguski A, Maguire R et al.. “Lifetime exposure to shift work and risk of multiple sclerosis: retrospective and prospective cohort studies in UK Biobank.” Occupational and environmental medicine (2026). PMID: 42431827 ↗

    L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG)
  264. [264]

    Comi G, Jeffery D, Kappos L et al.. “Placebo-controlled trial of oral laquinimod for multiple sclerosis.” The New England journal of medicine (2012). PMID: 22417253 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification
  265. [265]

    Rudick RA, Stuart WH, Calabresi PA et al.. “Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.” The New England journal of medicine (2006). PMID: 16510745 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  266. [266]

    Feinstein A, Amato MP, Brichetto G et al.. “Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis (CogEx): a randomised, blinded, sham-controlled trial.” The Lancet. Neurology (2023). PMID: 37739574 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
  267. [267]

    Bar-Or A, Dufek M, Budincevic H et al.. “Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study.” The Lancet. Neurology (2025). PMID: 40683275 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance
  268. [268]

    Svenningsson A, Frisell T, Burman J et al.. “Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.” The Lancet. Neurology (2022). PMID: 35841908 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Prognosis & Natural History
  269. [269]

    Braley TJ, Ehde DM, Alschuler KN et al.. “Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm trial.” The Lancet. Neurology (2024). PMID: 39424559 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
  270. [270]

    Zajicek J, Ball S, Wright D et al.. “Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.” The Lancet. Neurology (2013). PMID: 23856559 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Complications
  271. [271]

    Reilmann R, Anderson KE, Feigin A et al.. “Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.” The Lancet. Neurology (2024). PMID: 38280392 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification
  272. [272]

    Kappos L, Wolinsky JS, Giovannoni G et al.. “Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.” JAMA neurology (2020). PMID: 32511687 ↗

    L2RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
  273. [273]

    Kappos L, Bar-Or A, Cree BAC et al.. “Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.” Lancet (London, England) (2018). PMID: 29576505 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
  274. [274]

    Giovannoni G, Airas L, Bove R et al.. “Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.” Lancet (London, England) (2026). PMID: 42208561 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
  275. [275]

    Hauser SL, Giovannoni G, Montalban X et al.. “Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.” Lancet (London, England) (2026). PMID: 42208560 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
  276. [276]

    Goodman AD, Brown TR, Krupp LB et al.. “Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.” Lancet (London, England) (2009). PMID: 19249634 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
  277. [277]

    Aktas O, Smith MA, Rees WA et al.. “Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.” Annals of neurology (2021). PMID: 33724534 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
  278. [278]

    Piehl F, Alping P, Virtanen S et al.. “COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab.” Annals of neurology (2024). PMID: 38923558 ↗

    L2COHORTCited in: Severity, Staging & Risk Stratification, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  279. [279]

    Kjølhede T, Vissing K, Dalgas U. “Multiple sclerosis and progressive resistance training: a systematic review.” Multiple sclerosis (Houndmills, Basingstoke, England) (2012). PMID: 22760230 ↗

    L1SR_OBSCited in: Severity, Staging & Risk Stratification
  280. [280]

    Sahi N, Ciccarelli O, Houlden H et al.. “Unlocking Multiple Sclerosis Genetics: From Susceptibility to Severity.” Neurology (2025). PMID: 41004698 ↗

    L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification
  281. [281]

    Watanabe M, Isobe N, Niino M et al.. “Prevalence of, and Disability Due to, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Japan by the Fifth Nationwide Survey.” Neurology (2024). PMID: 39475688 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification
  282. [282]

    Harding K, Williams O, Willis M et al.. “Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.” JAMA neurology (2019). PMID: 30776055 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History, Prevention, Screening & Surveillance
  283. [283]

    Tur C, Carbonell-Mirabent P, Cobo-Calvo Á et al.. “Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis.” JAMA neurology (2023). PMID: 36534392 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification
  284. [284]

    Phillips Reindel KM, Bell AS, Goldberg EL et al.. “Exploring social moderators of telehealth treatment outcomes for adults with multiple sclerosis: A secondary analysis of a randomized controlled trial.” Rehabilitation psychology (2026). PMID: 42423672 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment
  285. [285]

    Williams T, Blackstone J, John N et al.. “Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.” Health technology assessment (Winchester, England) (2026). PMID: 42370465 ↗

    L1RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
  286. [286]

    Monreal E, Fernández-Velasco JI, Álvarez-Lafuente R et al.. “Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.” Brain : a journal of neurology (2024). PMID: 39101570 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  287. [287]

    Cree BAC, Hollenbach JA, Bove R et al.. “Silent progression in disease activity-free relapsing multiple sclerosis.” Annals of neurology (2019). PMID: 30851128 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
  288. [288]

    Meuth SG, Wolff S, Mück A et al.. “Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab.” Annals of neurology (2024). PMID: 39582359 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification, Prognosis & Natural History
  289. [289]

    Lillo Triguero L, Pilo de la Fuente B, Díaz Díaz J et al.. “Tetrahydrocannabinol/cannabidiol in the treatment of restless legs syndrome.” Journal of neurology (2026). PMID: 42387200 ↗

    L4TRIAL_NONRANDOMCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History
  290. [290]

    Kobelt G, Thompson A, Berg J et al.. “New insights into the burden and costs of multiple sclerosis in Europe.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 28273775 ↗

    L2OTHERCited in: Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care
  291. [291]

    Bayoumi A, Hasan KM, Thomas JA et al.. “Glymphatic dysfunction in multiple sclerosis and its association with disease pathology and disability.” Multiple sclerosis (Houndmills, Basingstoke, England) (2024). PMID: 39344166 ↗

    L3OTHERCited in: Severity, Staging & Risk Stratification
  292. [292]

    Patsopoulos NA, De Jager PL. “Genetic and gene expression signatures in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2020). PMID: 31965883 ↗

    L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification
  293. [293]

    Owen DR, Piccini P, Matthews PM. “Towards molecular imaging of multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2011). PMID: 21212087 ↗

    L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification
  294. [294]

    De León-Muñoz A, Rubio-Arias JÁ, Ávila-Gandía V et al.. “Effects of physical exercise on neurofilament light chain in multiple sclerosis and other neurological disorders: A systematic review.” Multiple sclerosis and related disorders (2026). PMID: 42413317 ↗

    L1SR_OBSCited in: Severity, Staging & Risk Stratification
  295. [295]

    Nabil Y, Mansour A, Mohamed AA et al.. “Comparative effects of pilates-based interventions on functional mobility, balance, fatigue, and quality of life in people with multiple sclerosis: a systematic review and network meta-analysis.” BMC sports science, medicine & rehabilitation (2026). PMID: 42400084 ↗

    L1SR_OBSCited in: Severity, Staging & Risk Stratification, Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
  296. [296]

    Kaveyee H, Etemadifar M, Abhari AP et al.. “Fingolimod for pediatric multiple sclerosis: The Ped-MS group systematic review and meta-analysis.” Multiple sclerosis and related disorders (2026). PMID: 42361660 ↗

    L1SR_OBSCited in: Severity, Staging & Risk Stratification, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Complications, Special Populations & Pregnancy, Prevention, Screening & Surveillance
  297. [297]

    Nash RA, Hutton GJ, Racke MK et al.. “High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.” JAMA neurology (2015). PMID: 25546364 ↗

    L4TRIAL_NONRANDOMCited in: Acute Management: Neurologic Emergencies & Attack Abortion, Neurorehabilitation, Symptomatic & Supportive Care, Complications
  298. [298]

    Marrie RA, Tremlett H, Kingwell E et al.. “Disparities in management and outcomes of myocardial infarction in multiple sclerosis: A matched cohort study.” Multiple sclerosis (Houndmills, Basingstoke, England) (2019). PMID: 31517571 ↗

    L2SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  299. [299]

    Soelberg K, Jarius S, Skejoe H et al.. “A population-based prospective study of optic neuritis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 28980518 ↗

    L2COHORTCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  300. [300]

    Lee S, Muccilli A, Schneider R et al.. “Acute central nervous system inflammation following COVID-19 vaccination: An observational cohort study.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 36840605 ↗

    L2COHORTCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  301. [301]

    Hardy TA, Reddel SW, Barnett MH et al.. “Atypical inflammatory demyelinating syndromes of the CNS.” The Lancet. Neurology (2016). PMID: 27478954 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Neurologic Emergencies & Attack Abortion
  302. [302]

    Yamout B, Gouider R, Al-Roughani R et al.. “Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines.” CNS drugs (2026). PMID: 41591715 ↗

    L1GUIDELINECited in: Acute Management: Neurologic Emergencies & Attack Abortion
  303. [303]

    Ness JM, Chabas D, Sadovnick AD et al.. “Clinical features of children and adolescents with multiple sclerosis.” Neurology (2007). PMID: 17438237 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Neurologic Emergencies & Attack Abortion
  304. [304]

    Wassmer E, Chitnis T, Pohl D et al.. “International Pediatric MS Study Group Global Members Symposium report.” Neurology (2016). PMID: 27572855 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Neurologic Emergencies & Attack Abortion
  305. [305]

    Croteau D, Flowers C, Kulick CG et al.. “Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab.” Neurology (2018). PMID: 29602912 ↗

    L4REVIEW_NARRATIVECited in: Acute Management: Neurologic Emergencies & Attack Abortion
  306. [306]

    Robinson MT, Barrett KM. “Emerging subspecialties in neurology: neuropalliative care.” Neurology (2014). PMID: 24862899 ↗

    L5OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  307. [307]

    Marrie RA, Elliott L, Marriott J et al.. “Comorbidity increases the risk of hospitalizations in multiple sclerosis.” Neurology (2014). PMID: 25540309 ↗

    L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  308. [308]

    Cortese I, Chaudhry V, So YT et al.. “Evidence-based guideline update: Plasmapheresis in neurologic disorders [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.” Neurology (2011). PMID: 21242498 ↗

    L1REVIEW_NARRATIVECited in: Acute Management: Neurologic Emergencies & Attack Abortion
  309. [309]

    Deiva K, Absoud M, Hemingway C et al.. “Acute idiopathic transverse myelitis in children: early predictors of relapse and disability.” Neurology (2014). PMID: 25540303 ↗

    L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  310. [310]

    Banwell B, Kennedy J, Sadovnick D et al.. “Incidence of acquired demyelination of the CNS in Canadian children.” Neurology (2009). PMID: 19153370 ↗

    L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  311. [311]

    Meier S, Willemse EAJ, Schaedelin S et al.. “Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.” JAMA neurology (2023). PMID: 36745446 ↗

    L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  312. [312]

    Puthenparampil M, Poggiali D, Causin F et al.. “Cortical relapses in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2015). PMID: 25791367 ↗

    L4CASE_REPORTCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  313. [313]

    Ahrabian D, Neill L, Bell R et al.. “Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2020). PMID: 32298216 ↗

    L4CASE_REPORTCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  314. [314]

    Giorgi L, Marignier R, Pique J et al.. “French guidelines for the diagnosis and management of MOG antibody-associated disease.” Revue neurologique (2025). PMID: 40494723 ↗

    L1GUIDELINECited in: Acute Management: Neurologic Emergencies & Attack Abortion
  315. [315]

    Keddie S, Smyth D, Keh RYS et al.. “Peripherin is a biomarker of axonal damage in peripheral nervous system disease.” Brain : a journal of neurology (2023). PMID: 37435933 ↗

    L3OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion, Prognosis & Natural History
  316. [316]

    Bellanti R, Keh RYS, Keddie S et al.. “Plasma periaxin is a biomarker of peripheral nerve demyelination.” Brain : a journal of neurology (2025). PMID: 40581376 ↗

    L3OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  317. [317]

    Tur C, Susin-Calle S, Otero-Romero S et al.. “Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosis.” Brain : a journal of neurology (2026). PMID: 42267539 ↗

    L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  318. [318]

    Hamedani AG, Thibault D, Willis AW. “Seasonal Variation in Neurologic Hospitalizations in the United States.” Annals of neurology (2022). PMID: 36515177 ↗

    L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  319. [319]

    Tallantyre EC, Vickaryous N, Anderson V et al.. “COVID-19 Vaccine Response in People with Multiple Sclerosis.” Annals of neurology (2021). PMID: 34687063 ↗

    L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  320. [320]

    Kalb R, Beier M, Benedict RH et al.. “Recommendations for cognitive screening and management in multiple sclerosis care.” Multiple sclerosis (Houndmills, Basingstoke, England) (2018). PMID: 30303036 ↗

    L1REVIEW_NARRATIVECited in: Acute Management: Neurologic Emergencies & Attack Abortion, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Neurorehabilitation, Symptomatic & Supportive Care, Prevention, Screening & Surveillance
  321. [321]

    Durozard P, Maarouf A, Boutiere C et al.. “Efficacy of rituximab in refractory RRMS.” Multiple sclerosis (Houndmills, Basingstoke, England) (2018). PMID: 29722639 ↗

    L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  322. [322]

    Roston S, Quick MH, Tisavipat N et al.. “Assessment of increased opening pressure in patients with multiple sclerosis and aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder.” Multiple sclerosis (Houndmills, Basingstoke, England) (2025). PMID: 40415648 ↗

    L4OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  323. [323]

    Schwarz T, Otto C, Jones TC et al.. “Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2022). PMID: 35575234 ↗

    L2OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  324. [324]

    Akrivaki A, Giannopapas V, Dimitriadou EM et al.. “Neuropathic Pain in Neuromyelitis Optica Spectrum Disorders: Prevalence and Management Strategies-A Systematic Review and Meta-Analysis.” Journal of clinical medicine (2026). PMID: 41753066 ↗

    L1SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  325. [325]

    Sredanović M, Bunoza B, Lehman I et al.. “Towards practical management of the Marburg variant of multiple sclerosis.” Multiple sclerosis and related disorders (2025). PMID: 41380461 ↗

    L4SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  326. [326]

    Craiu D, Dica AD, Pomeran C et al.. “Disease-Modifying Treatment Options in Very Early Onset Multiple Sclerosis-What Choices Are There for Onset Under 5 Years of Age? A Systematic Review.” Journal of clinical medicine (2025). PMID: 41303170 ↗

    L5SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  327. [327]

    Wang C, Liu Z, Zhou Y et al.. “Exploring the Potential Link Between Autoimmune Diseases and Pan-Cancer: A Multidatabase Mendelian Randomization Analysis.” Journal of immunology research (2025). PMID: 40322556 ↗

    L2SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  328. [328]

    Yuan S, Hou J, Yang X. “Social Determinants of Health, Nursing Care Quality, and Patient Outcomes in Neurological Disorders: A Systematic Review.” Risk management and healthcare policy (2026). PMID: 42221297 ↗

    L2SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion, Prevention, Screening & Surveillance
  329. [329]

    Chen J, Yang K. “Letter to the editor: comment on "primary visual cortex impairment due to trans-synaptic degeneration after optic neuritis: a systematic review of neuroimaging studies".” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 40845468 ↗

    L5SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  330. [330]

    Shilash OB, Alqahtani L, Alkhaibary A et al.. “Trigeminal neuralgia management in patients with multiple sclerosis: A systematic review of approaches and outcomes.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 40220576 ↗

    L5SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion
  331. [331]

    Fox RJ, Bar-Or A, Traboulsee A et al.. “Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.” The New England journal of medicine (2025). PMID: 40202696 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
  332. [332]

    Cohen JA, Barkhof F, Comi G et al.. “Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.” The New England journal of medicine (2010). PMID: 20089954 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  333. [333]

    Kappos L, Radue EW, O'Connor P et al.. “A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.” The New England journal of medicine (2010). PMID: 20089952 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  334. [334]

    Coles AJ, Compston DA, Selmaj KW et al.. “Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.” The New England journal of medicine (2008). PMID: 18946064 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History
  335. [335]

    Corboy JR, Fox RJ, Kister I et al.. “Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.” The Lancet. Neurology (2023). PMID: 37353277 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
  336. [336]

    Kappos L, Hartung HP, Freedman MS et al.. “Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.” The Lancet. Neurology (2014). PMID: 24613349 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  337. [337]

    Cree BAC, Cutter G, Wolinsky JS et al.. “Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet. Neurology (2020). PMID: 33222767 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  338. [338]

    Cohen JA, Comi G, Selmaj KW et al.. “Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.” The Lancet. Neurology (2019). PMID: 31492652 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), Prevention, Screening & Surveillance
  339. [339]

    Chataway J, De Angelis F, Connick P et al.. “Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.” The Lancet. Neurology (2020). PMID: 31981516 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  340. [340]

    Comi G, Kappos L, Selmaj KW et al.. “Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.” The Lancet. Neurology (2019). PMID: 31492651 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), Prevention, Screening & Surveillance
  341. [341]

    Confavreux C, O'Connor P, Comi G et al.. “Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet. Neurology (2014). PMID: 24461574 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  342. [342]

    Cortese M, Peng X, Edan G et al.. “Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression.” Neurology (2025). PMID: 40674673 ↗

    L2RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
  343. [343]

    Hemmer B, Wiendl H, Roth K et al.. “Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial.” JAMA neurology (2023). PMID: 36689214 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Prevention, Screening & Surveillance
  344. [344]

    Tanasescu R, Tench CR, Constantinescu CS et al.. “Hookworm Treatment for Relapsing Multiple Sclerosis: A Randomized Double-Blinded Placebo-Controlled Trial.” JAMA neurology (2020). PMID: 32539079 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Complications
  345. [345]

    Iaci JF, Parry TJ, Huang Z et al.. “Dalfampridine improves sensorimotor function in rats with chronic deficits after middle cerebral artery occlusion.” Stroke (2013). PMID: 23652269 ↗

    L5RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
  346. [346]

    Coles AJ, Twyman CL, Arnold DL et al.. “Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.” Lancet (London, England) (2012). PMID: 23122650 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  347. [347]

    Chataway J, Williams T, Li V et al.. “Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges.” The Lancet. Neurology (2024). PMID: 38365380 ↗

    L5TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  348. [348]

    Ontaneda D, Fox RJ, Chataway J. “Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.” The Lancet. Neurology (2015). PMID: 25772899 ↗

    L5TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder), Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  349. [349]

    Sormani MP, Bruzzi P. “MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials.” The Lancet. Neurology (2013). PMID: 23743084 ↗

    L1SR_OBSCited in: Long-term & Definitive Management (Evidence Ladder)
  350. [350]

    Salter A, Lancia S, Kowalec K et al.. “Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.” Neurology (2024). PMID: 38350062 ↗

    L2TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
  351. [351]

    Freedman MS. “Long-term follow-up of clinical trials of multiple sclerosis therapies.” Neurology (2011). PMID: 21205679 ↗

    L5TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder)
  352. [352]

    Waubant E, Banwell B, Wassmer E et al.. “Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG.” Neurology (2019). PMID: 31043474 ↗

    L1TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder)
  353. [353]

    Baker D, Herrod SS, Alvarez-Gonzalez C et al.. “Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.” JAMA neurology (2017). PMID: 28604916 ↗

    L4TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder)
  354. [354]

    Okuda DT, Kantarci O, Lebrun-Frénay C et al.. “Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome.” Annals of neurology (2022). PMID: 36401339 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  355. [355]

    Lublin FD, Cofield SS, Cutter GR et al.. “Randomized study combining interferon and glatiramer acetate in multiple sclerosis.” Annals of neurology (2013). PMID: 23424159 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  356. [356]

    Bermel RA, You X, Foulds P et al.. “Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.” Annals of neurology (2013). PMID: 23378325 ↗

    L2RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  357. [357]

    Goodman AD, Brown TR, Edwards KR et al.. “A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.” Annals of neurology (2010). PMID: 20976768 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  358. [358]

    Gärtner J, Hauser SL, Bar-Or A et al.. “Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.” Multiple sclerosis (Houndmills, Basingstoke, England) (2022). PMID: 35266417 ↗

    L2RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
  359. [359]

    Corboy JR, Fox RJ, Cutter G et al.. “DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial.” Multiple sclerosis (Houndmills, Basingstoke, England) (2025). PMID: 39834328 ↗

    L2RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  360. [360]

    Bar-Or A, Calabresi PA, Arnold D et al.. “Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.” Annals of neurology (2008). PMID: 18383069 ↗

    L4TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder)
  361. [361]

    Mascareñas-García M, Rivero-de-Aguilar A, Candal-Pedreira C et al.. “Distortion in the Communication of Nonsignificant Primary Outcomes: The Spin Strategy in Multiple Sclerosis Trials.” Annals of neurology (2026). PMID: 41586489 ↗

    L1SR_OBSCited in: Long-term & Definitive Management (Evidence Ladder)
  362. [362]

    Marrie RA, Sormani MP, Apap Mangion S et al.. “Improving the efficiency of clinical trials in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 37555492 ↗

    L5TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder)
  363. [363]

    Strijbis E, Mostert J, D'Haeseleer M et al.. “Diminishing returns of disease-modifying treatment in older participants of multiple sclerosis clinical trials.” Multiple sclerosis (Houndmills, Basingstoke, England) (2026). PMID: 41858174 ↗

    L2TRIAL_NONRANDOMCited in: Long-term & Definitive Management (Evidence Ladder)
  364. [364]

    Gerardi C, Bertele' V, Rossi S et al.. “Preapproval and postapproval evidence on drugs for multiple sclerosis.” Neurology (2018). PMID: 29695598 ↗

    L1REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Prevention, Screening & Surveillance
  365. [365]

    Ghezzi A, Amato MP, Makhani N et al.. “Pediatric multiple sclerosis: Conventional first-line treatment and general management.” Neurology (2016). PMID: 27572869 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder)
  366. [366]

    Scalfari A, Knappertz V, Cutter G et al.. “Mortality in patients with multiple sclerosis.” Neurology (2013). PMID: 23836941 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder), Complications
  367. [367]

    Tur C, Kalincik T, Oh J et al.. “Head-to-head drug comparisons in multiple sclerosis: Urgent action needed.” Neurology (2019). PMID: 31591277 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder)
  368. [368]

    Corboy JR, Weinshenker BG, Wingerchuk DM. “Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS.” Neurology (2018). PMID: 29685920 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder)
  369. [369]

    Miller AE, Chitnis T, Cohen BA et al.. “Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: Recommendations of the National Multiple Sclerosis Society.” JAMA neurology (2021). PMID: 33104165 ↗

    L1REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder)
  370. [370]

    Wootla B, Watzlawik JO, Warrington AE et al.. “Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases.” JAMA neurology (2015). PMID: 26389734 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder)
  371. [371]

    Zhuang Y, Meng J, Dai X et al.. “Vitamin D for multiple sclerosis as an adjuvant therapy: A network meta-analysis of randomized controlled trials.” Clinical nutrition (Edinburgh, Scotland) (2026). PMID: 42242131 ↗

    L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  372. [372]

    Yang FA, Chen HC, Wu PJ et al.. “Prescribing Resistance Training in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” American journal of physical medicine & rehabilitation (2026). PMID: 42155970 ↗

    L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  373. [373]

    Jabbari A, Esmaeili Gouvarchin Ghaleh H, Alimohammadi M et al.. “Effect of vitamin D3 supplementation on systemic inflammation and disease-specific markers in patients with autoimmune diseases: a comprehensive meta-analysis of randomized controlled trials.” Inflammopharmacology (2026). PMID: 41952022 ↗

    L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  374. [374]

    Hogenboom L, Schoof LG, Gelissen LMY et al.. “Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab.” European journal of neurology (2026). PMID: 42411923 ↗

    L2RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
  375. [375]

    Robertson D, Alvarez E, Steinman L et al.. “Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.” Frontiers in immunology (2026). PMID: 42292352 ↗

    L2RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  376. [376]

    Hamedani M, Lombardi G, Boffa G et al.. “Task-oriented virtual reality and brain functional plasticity in progressive multiple sclerosis: A randomized controlled trial on upper limb rehabilitation.” Multiple sclerosis (Houndmills, Basingstoke, England) (2026). PMID: 42265947 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care
  377. [377]

    Tallantyre EC, Planchon SM, Howard H et al.. “Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).” Multiple sclerosis (Houndmills, Basingstoke, England) (2026). PMID: 42218617 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment
  378. [378]

    Donkers SJ, Lohse KR, Melam GR et al.. “Translingual neural stimulation to improve gait and balance in multiple sclerosis: A randomized controlled trial.” Archives of physical medicine and rehabilitation (2026). PMID: 42150723 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  379. [379]

    Kiropoulos LA, Kilpatrick TJ, Kalincik T et al.. “A tailored cognitive behavioural therapy intervention for depression in those newly diagnosed with multiple sclerosis (ACTION-MS): A randomised, assessor-blinded, active comparator trial.” Journal of affective disorders (2026). PMID: 42134745 ↗

    L1RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  380. [380]

    Smirnov RA, Cantoni C, Lee K et al.. “Dynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple Sclerosis.” Neurology(R) neuroimmunology & neuroinflammation (2026). PMID: 41990287 ↗

    L4RCTCited in: Long-term & Definitive Management (Evidence Ladder)
  381. [381]

    Roos I, Leray E, Frascoli F et al.. “Delay from treatment start to full effect of immunotherapies for multiple sclerosis.” Brain : a journal of neurology (2020). PMID: 32947619 ↗

    L2OTHERCited in: Long-term & Definitive Management (Evidence Ladder)
  382. [382]

    Kalincik T, Cutter G, Spelman T et al.. “Defining reliable disability outcomes in multiple sclerosis.” Brain : a journal of neurology (2015). PMID: 26359291 ↗

    L2OTHERCited in: Long-term & Definitive Management (Evidence Ladder), Prevention, Screening & Surveillance
  383. [383]

    Moser T, Hitzl W, Lerda-Casaccia T et al.. “Propionic acid in multiple sclerosis: a phase 2b, double-blind, randomized placebo-controlled trial.” Brain : a journal of neurology (2026). PMID: 42402345 ↗

    L1OTHERCited in: Long-term & Definitive Management (Evidence Ladder), Neurorehabilitation, Symptomatic & Supportive Care
  384. [384]

    Palace J, Lin DY, Zeng D et al.. “Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders.” Brain : a journal of neurology (2019). PMID: 30938427 ↗

    L2OTHERCited in: Long-term & Definitive Management (Evidence Ladder)
  385. [385]

    Abrahamsson SV, Angelini DF, Dubinsky AN et al.. “Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.” Brain : a journal of neurology (2013). PMID: 23864273 ↗

    L4OTHERCited in: Long-term & Definitive Management (Evidence Ladder)
  386. [386]

    Cerono G, Cree BAC, Hauser SL et al.. “Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence.” Annals of neurology (2025). PMID: 40919837 ↗

    L2OTHERCited in: Long-term & Definitive Management (Evidence Ladder)
  387. [387]

    Mowry EM, Krupp LB, Milazzo M et al.. “Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis.” Annals of neurology (2010). PMID: 20437559 ↗

    L2OTHERCited in: Long-term & Definitive Management (Evidence Ladder)
  388. [388]

    Clanet MC, Wolinsky JS, Ashton RJ et al.. “Risk evaluation and monitoring in multiple sclerosis therapeutics.” Multiple sclerosis (Houndmills, Basingstoke, England) (2013). PMID: 24293456 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder)
  389. [389]

    Hartung HP, Aktas O, Boyko AN. “Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2014). PMID: 25344374 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder)
  390. [390]

    Banwell B. “Pediatric multiple sclerosis: The 2022 ECTRIMS lecture.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 37249099 ↗

    L5OTHERCited in: Long-term & Definitive Management (Evidence Ladder)
  391. [391]

    Cohen JA, Trojano M, Mowry EM et al.. “Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment.” Multiple sclerosis (Houndmills, Basingstoke, England) (2019). PMID: 31778094 ↗

    L5REVIEW_NARRATIVECited in: Long-term & Definitive Management (Evidence Ladder)
  392. [392]

    Rød BE, Høgestøl EA, Torkildsen Ø et al.. “Comparative effectiveness of rituximab and cladribine in relapsing-remitting multiple sclerosis: A target trial emulation.” Multiple sclerosis (Houndmills, Basingstoke, England) (2025). PMID: 40415655 ↗

    L2OTHERCited in: Long-term & Definitive Management (Evidence Ladder)
  393. [393]

    Wingerchuk DM, Noseworthy JH. “Randomized controlled trials to assess therapies for multiple sclerosis.” Neurology (2002). PMID: 11971125 ↗

    L5RCTCited in: History and Evolution of Treatment
  394. [394]

    Oh J, Arnold DL, Cree BAC et al.. “Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.” The New England journal of medicine (2025). PMID: 40202623 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis & Natural History
  395. [395]

    Krupp LB, Tardieu M, Amato MP et al.. “International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions.” Multiple sclerosis (Houndmills, Basingstoke, England) (2013). PMID: 23572237 ↗

    L5GUIDELINECited in: History and Evolution of Treatment, Special Populations & Pregnancy
  396. [396]

    Collongues N, Durand-Dubief F, Lebrun-Frenay C et al.. “Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society.” Multiple sclerosis (Houndmills, Basingstoke, England) (2024). PMID: 38357870 ↗

    L1GUIDELINECited in: History and Evolution of Treatment
  397. [397]

    Reich DS, Arnold DL, Vermersch P et al.. “Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.” The Lancet. Neurology (2021). PMID: 34418400 ↗

    L1RCTCited in: History and Evolution of Treatment, Prevention, Screening & Surveillance
  398. [398]

    Hartung HP, Gonsette R, König N et al.. “Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.” Lancet (London, England) (Unknown). PMID: 12504397 ↗

    L1RCTCited in: History and Evolution of Treatment
  399. [399]

    Hommes OR, Sørensen PS, Fazekas F et al.. “Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.” Lancet (London, England) (Unknown). PMID: 15451222 ↗

    L1RCTCited in: History and Evolution of Treatment
  400. [400]

    Barnes D, Hughes RA, Morris RW et al.. “Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.” Lancet (London, England) (1997). PMID: 9093250 ↗

    L1RCTCited in: History and Evolution of Treatment
  401. [401]

    Coles AJ, Wing M, Smith S et al.. “Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.” Lancet (London, England) (1999). PMID: 10568572 ↗

    L4RCTCited in: History and Evolution of Treatment
  402. [402]

    Lorefice L, Pellecchia MT. “Frailty across Neurological Diseases: Why Sex and Gender Matter.” Annals of neurology (2025). PMID: 41267611 ↗

    L5SR_OBSCited in: History and Evolution of Treatment
  403. [403]

    Siavoshi F, Smith MD, Cassard S et al.. “Fasting Mimicking Diets Reverse Accelerated Biological Aging in Multiple Sclerosis.” Annals of neurology (2025). PMID: 40970462 ↗

    L4RCTCited in: History and Evolution of Treatment
  404. [404]

    Cree BAC, Freedman MS, Gold M et al.. “Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Studies to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing and Progressive Forms of Multiple Sclerosis.” Annals of neurology (2025). PMID: 40698976 ↗

    L1RCTCited in: History and Evolution of Treatment
  405. [405]

    Hauser SL, Zielman R, Das Gupta A et al.. “Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 37691530 ↗

    L2RCTCited in: History and Evolution of Treatment
  406. [406]

    Giovannoni G, Soelberg Sorensen P, Cook S et al.. “Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 28870107 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis & Natural History
  407. [407]

    Krysko KM, Dobson R, Alroughani R et al.. “Family planning considerations in people with multiple sclerosis.” The Lancet. Neurology (2023). PMID: 36931808 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Special Populations & Pregnancy
  408. [408]

    Okai AF, Howard AM, Williams MJ et al.. “Advancing Care and Outcomes for African American Patients With Multiple Sclerosis.” Neurology (2022). PMID: 35470139 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  409. [409]

    Tremlett H, Zhao Y, Rieckmann P et al.. “New perspectives in the natural history of multiple sclerosis.” Neurology (2010). PMID: 20548045 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  410. [410]

    Filippi M, Preziosa P, Barkhof F et al.. “Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review.” JAMA neurology (2021). PMID: 33315071 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  411. [411]

    Rudick R, Polman C, Clifford D et al.. “Natalizumab: bench to bedside and beyond.” JAMA neurology (2013). PMID: 23128399 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  412. [412]

    Miller DH, Barkhof F, Frank JA et al.. “Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance.” Brain : a journal of neurology (2002). PMID: 12135961 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  413. [413]

    Miller DH, Grossman RI, Reingold SC et al.. “The role of magnetic resonance techniques in understanding and managing multiple sclerosis.” Brain : a journal of neurology (1998). PMID: 9549485 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  414. [414]

    Filippi M, Horsfield MA, Tofts PS et al.. “Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis.” Brain : a journal of neurology (1995). PMID: 8595489 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  415. [415]

    Hauser SL, Chan JR, Oksenberg JR. “Multiple sclerosis: Prospects and promise.” Annals of neurology (2013). PMID: 23955638 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
  416. [416]

    Weinshenker BG. “Natural history of multiple sclerosis.” Annals of neurology (1994). PMID: 8017890 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  417. [417]

    Noseworthy JH. “Clinical scoring methods for multiple sclerosis.” Annals of neurology (1994). PMID: 8017893 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  418. [418]

    Ludwin SK, Rao VTs, Moore CS et al.. “Astrocytes in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2016). PMID: 27207458 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  419. [419]

    Cheng Q, Cheng XJ, Jiang GX. “Multiple sclerosis in China--history and future.” Multiple sclerosis (Houndmills, Basingstoke, England) (2009). PMID: 19435753 ↗

    L4REVIEW_NARRATIVECited in: History and Evolution of Treatment
  420. [420]

    Costa SL, Genova HM, DeLuca J et al.. “Information processing speed in multiple sclerosis: Past, present, and future.” Multiple sclerosis (Houndmills, Basingstoke, England) (2016). PMID: 27207446 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  421. [421]

    Portaccio E, Amato MP. “Breastfeeding and post-partum relapses in multiple sclerosis patients.” Multiple sclerosis (Houndmills, Basingstoke, England) (2019). PMID: 30793658 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  422. [422]

    Carvalho AN, Lim JL, Nijland PG et al.. “Glutathione in multiple sclerosis: more than just an antioxidant?” Multiple sclerosis (Houndmills, Basingstoke, England) (2014). PMID: 24842957 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  423. [423]

    Miller DH, Fazekas F, Montalban X et al.. “Pregnancy, sex and hormonal factors in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2014). PMID: 24446387 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  424. [424]

    Ebers GC. “Natural history of primary progressive multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2004). PMID: 15218804 ↗

    L2REVIEW_NARRATIVECited in: History and Evolution of Treatment
  425. [425]

    Atwood LD, Wolf PA, Heard-Costa NL et al.. “Genetic variation in white matter hyperintensity volume in the Framingham Study.” Stroke (2004). PMID: 15143299 ↗

    L2OTHERCited in: History and Evolution of Treatment
  426. [426]

    Nicoletti A, Sofia V, Biondi R et al.. “Epilepsy and multiple sclerosis in Sicily: a population-based study.” Epilepsia (2003). PMID: 14636354 ↗

    L2OTHERCited in: History and Evolution of Treatment
  427. [427]

    Vaheb S, Hatef B, Mirani A et al.. “Effects of binaural beats on acute stress recovery and autonomic regulation in multiple sclerosis: a pilot double-blind randomized controlled trial.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42307797 ↗

    L1RCTCited in: History and Evolution of Treatment
  428. [428]

    Vermersch P, Arnould S, Gold R et al.. “Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study.” European journal of neurology (2026). PMID: 42257510 ↗

    L2RCTCited in: History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care
  429. [429]

    Baroni A, Fregna G, Azzolina D et al.. “Motor and cognitive effects of video game training in people with multiple sclerosis: a randomized controlled trial.” European journal of physical and rehabilitation medicine (2026). PMID: 42252956 ↗

    L1RCTCited in: History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care
  430. [430]

    Færk AK, Sellebjerg F, Lund JL et al.. “Cognitively stimulating activities in multiple sclerosis: Results of a randomized controlled trial.” Multiple sclerosis and related disorders (2026). PMID: 42214251 ↗

    L1RCTCited in: History and Evolution of Treatment
  431. [431]

    Sumowski JF, Levy S, Katz Sand I et al.. “Cognition in multiple sclerosis within the modern diagnostic and treatment era.” Brain : a journal of neurology (2026). PMID: 41293835 ↗

    L2OTHERCited in: History and Evolution of Treatment, Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  432. [432]

    Pisa M, Pansieri J, Yee S et al.. “Anterior optic pathway pathology in CNS demyelinating diseases.” Brain : a journal of neurology (2022). PMID: 35134111 ↗

    L4OTHERCited in: History and Evolution of Treatment
  433. [433]

    Shams H, Shao X, Santaniello A et al.. “Polygenic risk score association with multiple sclerosis susceptibility and phenotype in Europeans.” Brain : a journal of neurology (2023). PMID: 35253861 ↗

    L2OTHERCited in: History and Evolution of Treatment, Prevention, Screening & Surveillance
  434. [434]

    De Meo E, Filippi M, Trojano M et al.. “Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis.” Annals of neurology (2022). PMID: 35150168 ↗

    L2OTHERCited in: History and Evolution of Treatment, Special Populations & Pregnancy
  435. [435]

    Rae-Grant A, Day GS, Marrie RA et al.. “Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.” Neurology (2018). PMID: 29686116 ↗

    L1GUIDELINECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  436. [436]

    Spain RI, Paz Soldán MM, Freedman MS et al.. “Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.” Neurology (2025). PMID: 41397213 ↗

    L1RCTCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  437. [437]

    Landmeyer NC, Bürkner PC, Wiendl H et al.. “Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.” Neurology (2020). PMID: 32430312 ↗

    L1SR_OBSCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  438. [438]

    He A, Merkel B, Brown JWL et al.. “Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.” The Lancet. Neurology (2020). PMID: 32199096 ↗

    L2COHORTCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
  439. [439]

    Otero-Romero S, Lebrun-Frénay C, Reyes S et al.. “ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 37293841 ↗

    L1SR_OBSCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Special Populations & Pregnancy, Prevention, Screening & Surveillance
  440. [440]

    Lindå H, von Heijne A, Major EO et al.. “Progressive multifocal leukoencephalopathy after natalizumab monotherapy.” The New England journal of medicine (2009). PMID: 19741229 ↗

    L4CASE_REPORTCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  441. [441]

    Wenning W, Haghikia A, Laubenberger J et al.. “Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.” The New England journal of medicine (2009). PMID: 19741228 ↗

    L4CASE_REPORTCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  442. [442]

    Graves JS, Krysko KM, Hua LH et al.. “Ageing and multiple sclerosis.” The Lancet. Neurology (2022). PMID: 36216015 ↗

    L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  443. [443]

    Benkert P, Meier S, Schaedelin S et al.. “Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.” The Lancet. Neurology (2022). PMID: 35182510 ↗

    L2OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  444. [444]

    Chitnis T, Ghezzi A, Bajer-Kornek B et al.. “Pediatric multiple sclerosis: Escalation and emerging treatments.” Neurology (2016). PMID: 27572854 ↗

    L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  445. [445]

    Egan RA, Kawasaki A. “Tadpole pupil.” Neurology (2013). PMID: 23479467 ↗

    L5OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Special Populations & Pregnancy
  446. [446]

    Spelman T, Magyari M, Piehl F et al.. “Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.” JAMA neurology (2021). PMID: 34398221 ↗

    L2OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  447. [447]

    Frisoni GB, Aho E, Brayne C et al.. “Alzheimer's disease outlook: controversies and future directions.” Lancet (London, England) (2025). PMID: 40997840 ↗

    L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Neurorehabilitation, Symptomatic & Supportive Care, Complications, Prevention, Screening & Surveillance
  448. [448]

    Comi G, Radaelli M, Soelberg Sørensen P. “Evolving concepts in the treatment of relapsing multiple sclerosis.” Lancet (London, England) (2016). PMID: 27889192 ↗

    L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  449. [449]

    Androdias G, Lünemann JD, Maillart E et al.. “De-escalating and discontinuing disease-modifying therapies in multiple sclerosis.” Brain : a journal of neurology (2025). PMID: 39707906 ↗

    L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History, Special Populations & Pregnancy
  450. [450]

    Bosanac T, Hughes RO, Engber T et al.. “Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy.” Brain : a journal of neurology (2021). PMID: 33964142 ↗

    L5OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Prognosis & Natural History
  451. [451]

    Scolding NJ, Pasquini M, Reingold SC et al.. “Cell-based therapeutic strategies for multiple sclerosis.” Brain : a journal of neurology (2017). PMID: 29053779 ↗

    L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  452. [452]

    Camara-Lemarroy CR, Metz L, Meddings JB et al.. “The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics.” Brain : a journal of neurology (2018). PMID: 29860380 ↗

    L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  453. [453]

    Brittain G, Roldan E, Alexander T et al.. “The Role of Chimeric Antigen Receptor T-Cell Therapy in Immune-Mediated Neurological Diseases.” Annals of neurology (2024). PMID: 39015040 ↗

    L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  454. [454]

    Fine AJ, Sorbello A, Kortepeter C et al.. “Progressive multifocal leukoencephalopathy after natalizumab discontinuation.” Annals of neurology (2014). PMID: 24242357 ↗

    L4OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  455. [455]

    Koralnik IJ. “Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?” Annals of neurology (2006). PMID: 16862584 ↗

    L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  456. [456]

    Berger JR, Houff S. “Opportunistic infections and other risks with newer multiple sclerosis therapies.” Annals of neurology (2009). PMID: 19399841 ↗

    L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Complications, Prevention, Screening & Surveillance
  457. [457]

    Montalban X, Gold R, Thompson AJ et al.. “ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2018). PMID: 29353550 ↗

    L1OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Special Populations & Pregnancy
  458. [458]

    Sanai SA, Saini V, Benedict RH et al.. “Aging and multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2016). PMID: 26895718 ↗

    L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  459. [459]

    Abboud H, Hill E, Siddiqui J et al.. “Neuromodulation in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 29115915 ↗

    L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation, Neurorehabilitation, Symptomatic & Supportive Care
  460. [460]

    Frisell T, Hedberg S, Piehl F. “Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study.” Annals of neurology (2026). PMID: 42310849 ↗

    L2COHORTCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation
  461. [461]

    Rudick RA, Miller D, Hass S et al.. “Health-related quality of life in multiple sclerosis: effects of natalizumab.” Annals of neurology (2007). PMID: 17696126 ↗

    L2RCTCited in: Neurorehabilitation, Symptomatic & Supportive Care, Complications
  462. [462]

    Cree BA, Kornyeyeva E, Goodin DS. “Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis.” Annals of neurology (2010). PMID: 20695007 ↗

    L2RCTCited in: Neurorehabilitation, Symptomatic & Supportive Care
  463. [463]

    Panitch HS, Thisted RA, Smith RA et al.. “Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.” Annals of neurology (2006). PMID: 16634036 ↗

    L1RCTCited in: Neurorehabilitation, Symptomatic & Supportive Care
  464. [464]

    Snetselaar LG, Cheek JJ, Fox SS et al.. “Efficacy of Diet on Fatigue and Quality of Life in Multiple Sclerosis: A Systematic Review and Network Meta-analysis of Randomized Trials.” Neurology (2022). PMID: 36257717 ↗

    L1SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care, Prognosis & Natural History
  465. [465]

    Marrie RA, Miller A, Sormani MP et al.. “Recommendations for observational studies of comorbidity in multiple sclerosis.” Neurology (2016). PMID: 26865523 ↗

    L5SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care, Complications
  466. [466]

    Cano Porras D, Siemonsma P, Inzelberg R et al.. “Advantages of virtual reality in the rehabilitation of balance and gait: Systematic review.” Neurology (2018). PMID: 29720544 ↗

    L2SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care
  467. [467]

    Hauser SL. “Advances in Multiple Sclerosis.” The New England journal of medicine (2026). PMID: 42384871 ↗

    L5REVIEW_NARRATIVECited in: Neurorehabilitation, Symptomatic & Supportive Care
  468. [468]

    Sihvonen AJ, Särkämö T, Leo V et al.. “Music-based interventions in neurological rehabilitation.” The Lancet. Neurology (2017). PMID: 28663005 ↗

    L5REVIEW_NARRATIVECited in: Neurorehabilitation, Symptomatic & Supportive Care
  469. [469]

    Chiaravalloti ND, DeLuca J. “Cognitive impairment in multiple sclerosis.” The Lancet. Neurology (2008). PMID: 19007738 ↗

    L5REVIEW_NARRATIVECited in: Neurorehabilitation, Symptomatic & Supportive Care
  470. [470]

    Kluger BM, Hudson P, Hanson LC et al.. “Palliative care to support the needs of adults with neurological disease.” The Lancet. Neurology (2023). PMID: 37353280 ↗

    L5REVIEW_NARRATIVECited in: Neurorehabilitation, Symptomatic & Supportive Care, Prevention, Screening & Surveillance
  471. [471]

    McKay KA, Manouchehrinia A, Berrigan L et al.. “Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis.” JAMA neurology (2019). PMID: 31206130 ↗

    L2OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
  472. [472]

    Feinstein A, Bar-Or A, Benedict RHB et al.. “Is multiple sclerosis-related depression different from depression in general? The data for and against.” Brain : a journal of neurology (2025). PMID: 41251688 ↗

    L5REVIEW_NARRATIVECited in: Neurorehabilitation, Symptomatic & Supportive Care
  473. [473]

    Rodrigues P, Frare JM, Ruviaro NA et al.. “Advanced oxidation protein products activated TRPA1 in a neuropathic multiple sclerosis model.” Brain : a journal of neurology (2026). PMID: 40819275 ↗

    L5OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
  474. [474]

    Eijlers AJC, van Geest Q, Dekker I et al.. “Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.” Brain : a journal of neurology (2018). PMID: 30169585 ↗

    L2OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
  475. [475]

    Hobart JC, Riazi A, Thompson AJ et al.. “Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88).” Brain : a journal of neurology (2005). PMID: 16280352 ↗

    L5OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
  476. [476]

    de Groot V, Beckerman H, Uitdehaag BM et al.. “The usefulness of evaluative outcome measures in patients with multiple sclerosis.” Brain : a journal of neurology (2006). PMID: 16956906 ↗

    L2OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
  477. [477]

    Pan S, Chan JR. “Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis.” Annals of neurology (2021). PMID: 34402546 ↗

    L5REVIEW_NARRATIVECited in: Neurorehabilitation, Symptomatic & Supportive Care
  478. [478]

    Petzold A, Mondria T, Kuhle J et al.. “Evidence for acute neurotoxicity after chemotherapy.” Annals of neurology (2010). PMID: 21194151 ↗

    L2OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
  479. [479]

    Kalsi V, Gonzales G, Popat R et al.. “Botulinum injections for the treatment of bladder symptoms of multiple sclerosis.” Annals of neurology (2007). PMID: 17890635 ↗

    L4OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
  480. [480]

    Axthelm MK, Bourdette DN, Marracci GH et al.. “Japanese macaque encephalomyelitis: a spontaneous multiple sclerosis-like disease in a nonhuman primate.” Annals of neurology (2011). PMID: 21674589 ↗

    L4OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
  481. [481]

    Kalb R, Brown TR, Coote S et al.. “Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course.” Multiple sclerosis (Houndmills, Basingstoke, England) (2020). PMID: 32323606 ↗

    L1OTHERCited in: Neurorehabilitation, Symptomatic & Supportive Care
  482. [482]

    Lavorgna L, Brigo F, Moccia M et al.. “e-Health and multiple sclerosis: An update.” Multiple sclerosis (Houndmills, Basingstoke, England) (2018). PMID: 30231004 ↗

    L5REVIEW_NARRATIVECited in: Neurorehabilitation, Symptomatic & Supportive Care
  483. [483]

    López-Andaur R, Vásquez-Carrasco E, Guerra-Labbé L et al.. “Effectiveness of Immersive and Non-Immersive Virtual Reality Interventions on Cognitive Function in People with Multiple Sclerosis: A Systematic Review.” Journal of clinical medicine (2026). PMID: 42355702 ↗

    L2SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care
  484. [484]

    Santamaría G, Jiménez-Callejo E, Rodríguez López N et al.. “Effects of Aquatic Therapy on Fatigue, Mobility, Physical Function, and Quality of Life in People with Multiple Sclerosis: A Systematic Review and Meta-Analysis.” Journal of functional morphology and kinesiology (2026). PMID: 42346748 ↗

    L1SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care
  485. [485]

    Lagrèze WA, Küchlin S, Ihorst G et al.. “Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study.” The Lancet. Neurology (2021). PMID: 34800417 ↗

    L1RCTCited in: Complications
  486. [486]

    Freeman J, Hendrie W, Jarrett L et al.. “Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis.” The Lancet. Neurology (2019). PMID: 31301748 ↗

    L1RCTCited in: Complications
  487. [487]

    Riva N, Mora G, Sorarù G et al.. “Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.” The Lancet. Neurology (2018). PMID: 30554828 ↗

    L1RCTCited in: Complications
  488. [488]

    Kapoor R, Furby J, Hayton T et al.. “Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.” The Lancet. Neurology (2010). PMID: 20621711 ↗

    L1RCTCited in: Complications
  489. [489]

    Burt RK, Loh Y, Cohen B et al.. “Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.” The Lancet. Neurology (2009). PMID: 19186105 ↗

    L4TRIAL_NONRANDOMCited in: Complications
  490. [490]

    Sormani MP, Muraro PA, Schiavetti I et al.. “Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.” Neurology (2017). PMID: 28455383 ↗

    L1SR_OBSCited in: Complications
  491. [491]

    Marrie RA, Maxwell C, Mahar A et al.. “Cancer Incidence and Mortality Rates in Multiple Sclerosis: A Matched Cohort Study.” Neurology (2020). PMID: 33239364 ↗

    L3COHORTCited in: Complications
  492. [492]

    Learmonth YC, P Herring M, Russell DI et al.. “Safety of exercise training in multiple sclerosis: An updated systematic review and meta-analysis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 37880997 ↗

    L1SR_OBSCited in: Complications
  493. [493]

    Stefanou MI, Palaiodimou L, Theodorou A et al.. “Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 36722184 ↗

    L1SR_OBSCited in: Complications
  494. [494]

    Haghikia A, Langer-Gould A, Rellensmann G et al.. “Natalizumab use during the third trimester of pregnancy.” JAMA neurology (2014). PMID: 24821217 ↗

    L4CASE_REPORTCited in: Complications, Special Populations & Pregnancy
  495. [495]

    Hession RM, Sharma V, Spiegel DE et al.. “Multiple sclerosis disease progression and paradichlorobenzene: a tale of mothballs and toilet cleaner.” JAMA neurology (2014). PMID: 24343157 ↗

    L4CASE_REPORTCited in: Complications
  496. [496]

    Kalincik T, Sharmin S, Roos I et al.. “Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.” JAMA neurology (2023). PMID: 37437240 ↗

    L3OTHERCited in: Complications
  497. [497]

    Maier CM, Yu F, Nishi T et al.. “Interferon-beta fails to protect in a model of transient focal stroke.” Stroke (2006). PMID: 16514094 ↗

    L5OTHERCited in: Complications, Prognosis & Natural History
  498. [498]

    Rodgers J, Friede T, Vonberg FW et al.. “The impact of smoking cessation on multiple sclerosis disease progression.” Brain : a journal of neurology (2022). PMID: 34623418 ↗

    L2OTHERCited in: Complications
  499. [499]

    Kalincik T, Sharmin S, Roos I et al.. “Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.” Brain : a journal of neurology (2026). PMID: 40755195 ↗

    L3OTHERCited in: Complications
  500. [500]

    Kingwell E, Leray E, Zhu F et al.. “Multiple sclerosis: effect of beta interferon treatment on survival.” Brain : a journal of neurology (2019). PMID: 30883636 ↗

    L3OTHERCited in: Complications
  501. [501]

    Tecchio F, Zito G, Zappasodi F et al.. “Intra-cortical connectivity in multiple sclerosis: a neurophysiological approach.” Brain : a journal of neurology (2008). PMID: 18502782 ↗

    L4OTHERCited in: Complications
  502. [502]

    Hurley MJ, Deacon RMJ, Chan AWE et al.. “Reversal of behavioural phenotype by the cannabinoid-like compound VSN16R in fragile X syndrome mice.” Brain : a journal of neurology (2022). PMID: 34196695 ↗

    L5OTHERCited in: Complications
  503. [503]

    Scalfari A, Neuhaus A, Degenhardt A et al.. “The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.” Brain : a journal of neurology (2010). PMID: 20534650 ↗

    L2OTHERCited in: Complications, Prevention, Screening & Surveillance
  504. [504]

    Sabel CE, Pearson JF, Mason DF et al.. “The latitude gradient for multiple sclerosis prevalence is established in the early life course.” Brain : a journal of neurology (2021). PMID: 33704407 ↗

    L2OTHERCited in: Complications
  505. [505]

    Diebold M, Galli E, Kopf A et al.. “Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.” Annals of neurology (2022). PMID: 35170072 ↗

    L2OTHERCited in: Complications
  506. [506]

    Weiner HL. “The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?” Annals of neurology (2009). PMID: 19334069 ↗

    L5REVIEW_NARRATIVECited in: Complications
  507. [507]

    Khan O, Filippi M, Freedman MS et al.. “Chronic cerebrospinal venous insufficiency and multiple sclerosis.” Annals of neurology (2010). PMID: 20373339 ↗

    L5OTHERCited in: Complications
  508. [508]

    Witt L, Dost-Kovalsky K, Friedmann N et al.. “Ofatumumab-exposed breastfeeding in multiple sclerosis patients.” Multiple sclerosis (Houndmills, Basingstoke, England) (2025). PMID: 39757874 ↗

    L4OTHERCited in: Complications
  509. [509]

    Azeem MH, Shakeel R, Hassan D et al.. “Multimodal benefits of VR-based treadmill training in multiple sclerosis: A systematic review.” Multiple sclerosis and related disorders (2026). PMID: 42217431 ↗

    L1SR_OBSCited in: Complications, Prevention, Screening & Surveillance
  510. [510]

    Avedillo-Salas A, Martínez LB, Fanlo-Villacampa A et al.. “Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review.” Journal of neurology (2026). PMID: 42018029 ↗

    L1SR_OBSCited in: Complications
  511. [511]

    Grandidge L, Mohamed Abu Baker A, Kennish S et al.. “Suprapubic catheter insertion in people with multiple sclerosis: long-term complications and survival in a retrospective cohort study.” Journal of rehabilitation medicine (2026). PMID: 42237591 ↗

    L2COHORTCited in: Complications
  512. [512]

    Njohjam MN, Ngoule MO, Niakam TF. “Biological sex differences in neurodegenerative diseases in Africa: a scoping review of evidence and research gaps.” BMC neurology (2026). PMID: 42414949 ↗

    L2SR_OBSCited in: Complications
  513. [513]

    Moradi A, Ebrahimian A, Talebi M et al.. “The association between depressive symptoms and sleep quality in patients with multiple sclerosis: a systematic review and meta-analysis.” BMC neurology (2026). PMID: 42298462 ↗

    L3SR_OBSCited in: Complications
  514. [514]

    Kuhle J, Pohl C, Mehling M et al.. “Lack of association between antimyelin antibodies and progression to multiple sclerosis.” The New England journal of medicine (2007). PMID: 17251533 ↗

    L2RCTCited in: Prognosis & Natural History
  515. [515]

    Metz LM, Li DKB, Traboulsee AL et al.. “Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis.” The New England journal of medicine (2017). PMID: 28564557 ↗

    L1RCTCited in: Prognosis & Natural History
  516. [516]

    Bovis F, Signori A, Carmisciano L et al.. “Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas.” Annals of neurology (2018). PMID: 30179270 ↗

    L2SR_OBSCited in: Prognosis & Natural History
  517. [517]

    Lublin FD, Reingold SC, Cohen JA et al.. “Defining the clinical course of multiple sclerosis: the 2013 revisions.” Neurology (2014). PMID: 24871874 ↗

    L5OTHERCited in: Prognosis & Natural History
  518. [518]

    Neyal N, Nathoo N, Cathcart-Rake EJ et al.. “Gender-affirming interventions and prognosis in multiple sclerosis.” Multiple sclerosis (Houndmills, Basingstoke, England) (2025). PMID: 40462266 ↗

    L4OTHERCited in: Prognosis & Natural History
  519. [519]

    Gafson A, Craner MJ, Matthews PM. “Personalised medicine for multiple sclerosis care.” Multiple sclerosis (Houndmills, Basingstoke, England) (2016). PMID: 27672137 ↗

    L5REVIEW_NARRATIVECited in: Prognosis & Natural History
  520. [520]

    Leaviss J, Booth A, Coyle D et al.. “Effectiveness of non-pharmacological interventions for fatigue in adults with long-term conditions: a synopsis of the EIFFEL mixed-methods evidence synthesis.” Health technology assessment (Winchester, England) (2026). PMID: 42366788 ↗

    L2SR_OBSCited in: Prognosis & Natural History
  521. [521]

    Voskuhl RR, Wang H, Wu TC et al.. “Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.” The Lancet. Neurology (2015). PMID: 26621682 ↗

    L1RCTCited in: Special Populations & Pregnancy
  522. [522]

    Goyne C, Fair AE, Yilmaz D et al.. “Epigenetic Aging in Pediatric-Onset Multiple Sclerosis.” Neurology (2025). PMID: 40460354 ↗

    L2OTHERCited in: Special Populations & Pregnancy
  523. [523]

    Gavoille A, Rollot F, Casey R et al.. “Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis.” JAMA neurology (2025). PMID: 40758347 ↗

    L2OTHERCited in: Special Populations & Pregnancy
  524. [524]

    McKay KA, Friberg E, Razaz N et al.. “Long-term Socioeconomic Outcomes Associated With Pediatric-Onset Multiple Sclerosis.” JAMA neurology (2021). PMID: 33616605 ↗

    L2OTHERCited in: Special Populations & Pregnancy
  525. [525]

    Benallegue N, Rollot F, Wiertlewski S et al.. “Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.” JAMA neurology (2024). PMID: 38345791 ↗

    L2OTHERCited in: Special Populations & Pregnancy
  526. [526]

    Mexhitaj I, Nyirenda MH, Li R et al.. “Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis.” Brain : a journal of neurology (2019). PMID: 30759186 ↗

    L3OTHERCited in: Special Populations & Pregnancy
  527. [527]

    Eissman JM, Dumitrescu L, Mahoney ER et al.. “Sex differences in the genetic architecture of cognitive resilience to Alzheimer's disease.” Brain : a journal of neurology (2022). PMID: 35552371 ↗

    L3OTHERCited in: Special Populations & Pregnancy
  528. [528]

    Gaitsch H, Franklin RJM, Reich DS. “Cell-free DNA-based liquid biopsies in neurology.” Brain : a journal of neurology (2023). PMID: 36408894 ↗

    L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
  529. [529]

    Hay CM, Mahjoub A, Vidarsson L et al.. “Retinal hyper-reflective foci link retinal and cortical pathology in paediatric multiple sclerosis.” Brain : a journal of neurology (2026). PMID: 42381479 ↗

    L4OTHERCited in: Special Populations & Pregnancy
  530. [530]

    Kadowaki A, Saga R, Lin Y et al.. “Gut microbiota-dependent CCR9+CD4+ T cells are altered in secondary progressive multiple sclerosis.” Brain : a journal of neurology (2019). PMID: 30770703 ↗

    L3OTHERCited in: Special Populations & Pregnancy
  531. [531]

    Margoni M, Storelli L, Pagani E et al.. “Subventricular Zone Microstructure in Pediatric-Onset Multiple Sclerosis.” Annals of neurology (2025). PMID: 39825739 ↗

    L4OTHERCited in: Special Populations & Pregnancy
  532. [532]

    de Mol CL, Jansen PR, Muetzel RL et al.. “Polygenic Multiple Sclerosis Risk and Population-Based Childhood Brain Imaging.” Annals of neurology (2020). PMID: 32162725 ↗

    L4OTHERCited in: Special Populations & Pregnancy
  533. [533]

    Munger KL, Hongell K, Cortese M et al.. “Epstein-barr virus and multiple sclerosis risk in the finnish maternity cohort.” Annals of neurology (2019). PMID: 31226219 ↗

    L3OTHERCited in: Special Populations & Pregnancy
  534. [534]

    De Meo E, Bonacchi R, Moiola L et al.. “Early Predictors of 9-Year Disability in Pediatric Multiple Sclerosis.” Annals of neurology (2021). PMID: 33598931 ↗

    L2OTHERCited in: Special Populations & Pregnancy
  535. [535]

    Fadda G, Banwell B, Elliott C et al.. “Slowly Expanding Lesions Differentiate Pediatric Multiple Sclerosis from Myelin Oligodendrocyte Glycoprotein Antibody Disease.” Annals of neurology (2024). PMID: 39243229 ↗

    L3OTHERCited in: Special Populations & Pregnancy
  536. [536]

    Yam C, Jokubaitis V, Hellwig K et al.. “MS, pregnancy and COVID-19.” Multiple sclerosis (Houndmills, Basingstoke, England) (2020). PMID: 32924838 ↗

    L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
  537. [537]

    Proschmann U, Thomas K, Thiel S et al.. “Natalizumab during pregnancy and lactation.” Multiple sclerosis (Houndmills, Basingstoke, England) (2017). PMID: 28857686 ↗

    L4OTHERCited in: Special Populations & Pregnancy
  538. [538]

    Szaflik P, Nowakowska-Lipiec K. “Instrumented Timed Up and Go (iTUG): A Systematic Review of Parameters Across Healthy, Older, and Neurological Populations.” Journal of clinical medicine (2026). PMID: 42123041 ↗

    L5SR_OBSCited in: Special Populations & Pregnancy
  539. [539]

    Buijze MSJ, de Mol CL, Loudon SE et al.. “A systematic review of the clinical utility of retinal optical coherence tomography in childhood acquired demyelinating syndromes.” Multiple sclerosis and related disorders (2026). PMID: 42048775 ↗

    L1SR_OBSCited in: Special Populations & Pregnancy
  540. [540]

    Ebne-Ali-Heydari Y, Ramezani A, Jozayi A et al.. “Natalizumab for pediatric multiple sclerosis: a systematic review and meta-analysis.” Therapeutic advances in neurological disorders (2026). PMID: 42027697 ↗

    L1SR_OBSCited in: Special Populations & Pregnancy
  541. [541]

    Najibi A, Bazmi S, Moradi M et al.. “Association between hypertension status and severity and tinnitus: a cross-sectional analysis of the Fasa adult cohort study.” BMJ open (2026). PMID: 42259562 ↗

    L4COHORTCited in: Special Populations & Pregnancy, Prevention, Screening & Surveillance
  542. [542]

    Amini F, Everett K, Zhu F et al.. “Phenotyping healthcare use before pediatric-onset multiple sclerosis, including by sex and age: A matched cohort study.” Multiple sclerosis (Houndmills, Basingstoke, England) (2026). PMID: 42175615 ↗

    L2COHORTCited in: Special Populations & Pregnancy
  543. [543]

    Chitnis T, Banwell B, Kappos L et al.. “Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.” The Lancet. Neurology (2021). PMID: 34800398 ↗

    L1RCTCited in: Prevention, Screening & Surveillance
  544. [544]

    Zamboni P, Tesio L, Galimberti S et al.. “Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis: A Randomized Clinical Trial.” JAMA neurology (2018). PMID: 29150995 ↗

    L1RCTCited in: Prevention, Screening & Surveillance
  545. [545]

    Comi G, Pulizzi A, Rovaris M et al.. “Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.” Lancet (London, England) (2008). PMID: 18572078 ↗

    L1RCTCited in: Prevention, Screening & Surveillance
  546. [546]

    Koch MW, Sage K, Kaur S et al.. “Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial.” Neurology (2021). PMID: 34038379 ↗

    L4TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance
  547. [547]

    Moreno B, Hevia H, Santamaria M et al.. “Methylthioadenosine reverses brain autoimmune disease.” Annals of neurology (2006). PMID: 16786535 ↗

    L4RCTCited in: Prevention, Screening & Surveillance
  548. [548]

    Khan O, Rieckmann P, Boyko A et al.. “Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.” Annals of neurology (2013). PMID: 23686821 ↗

    L1RCTCited in: Prevention, Screening & Surveillance
  549. [549]

    Comi G, Cohen JA, Arnold DL et al.. “Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.” Annals of neurology (2011). PMID: 21280077 ↗

    L1RCTCited in: Prevention, Screening & Surveillance
  550. [550]

    Hernán MA, Alonso A, Hernández-Díaz S. “Tetanus vaccination and risk of multiple sclerosis: a systematic review.” Neurology (2006). PMID: 16864810 ↗

    L3SR_OBSCited in: Prevention, Screening & Surveillance
  551. [551]

    Muraro PA, Zito A, Signori A et al.. “Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study.” Annals of neurology (2025). PMID: 40251896 ↗

    L2COHORTCited in: Prevention, Screening & Surveillance
  552. [552]

    Lubetzki C, Zalc B, Williams A et al.. “Remyelination in multiple sclerosis: from basic science to clinical translation.” The Lancet. Neurology (2020). PMID: 32702337 ↗

    L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
  553. [553]

    Handunnetthi L, Ramagopalan SV, Ebers GC. “Multiple sclerosis, vitamin D, and HLA-DRB1*15.” Neurology (2010). PMID: 20530326 ↗

    L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
  554. [554]

    Wang Y, Liang J, Fang Y et al.. “Burden of Common Neurologic Diseases in Asian Countries, 1990-2019: An Analysis for the Global Burden of Disease Study 2019.” Neurology (2023). PMID: 37015823 ↗

    L2OTHERCited in: Prevention, Screening & Surveillance
  555. [555]

    Marriott JJ, Miyasaki JM, Gronseth G et al.. “Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.” Neurology (2010). PMID: 20439849 ↗

    L1REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
  556. [556]

    Jain N, Bhatti MT. “Fingolimod-associated macular edema: incidence, detection, and management.” Neurology (2012). PMID: 22371414 ↗

    L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
  557. [557]

    Solomon AJ, Naismith RT, Cross AH. “Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice.” Neurology (2018). PMID: 30381369 ↗

    L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
  558. [558]

    Grimaldi L, Papeix C, Hamon Y et al.. “Vaccines and the Risk of Hospitalization for Multiple Sclerosis Flare-Ups.” JAMA neurology (2023). PMID: 37669073 ↗

    L3OTHERCited in: Prevention, Screening & Surveillance
  559. [559]

    Brandt AU, Sy M, Bellmann-Strobl J et al.. “Association of a Marker of N-Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration.” JAMA neurology (2021). PMID: 33970182 ↗

    L4OTHERCited in: Prevention, Screening & Surveillance
  560. [560]

    Langer-Gould A, Qian L, Tartof SY et al.. “Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases.” JAMA neurology (2014). PMID: 25329096 ↗

    L3OTHERCited in: Prevention, Screening & Surveillance
  561. [561]

    Alsaid HM, Mohammed SS, Fayez ES et al.. “Effect of brain gym on cognition, manual dexterity and bimanual co-ordination in patients with multiple sclerosis.” Multiple sclerosis and related disorders (2026). PMID: 42202496 ↗

    L4RCTCited in: Prevention, Screening & Surveillance
  562. [562]

    Bittner S, Oh J, Havrdová EK et al.. “The potential of serum neurofilament as biomarker for multiple sclerosis.” Brain : a journal of neurology (2021). PMID: 34180982 ↗

    L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
  563. [563]

    Arlt FA, Miske R, Appeltshauser L et al.. “Septin multimer autoantibodies in severe motor neuropathy mimicking lower motor neuron disease.” Brain : a journal of neurology (2026). PMID: 42252093 ↗

    L3OTHERCited in: Prevention, Screening & Surveillance
  564. [564]

    Wentling M, Lopez-Gomez C, Park HJ et al.. “A metabolic perspective on CSF-mediated neurodegeneration in multiple sclerosis.” Brain : a journal of neurology (2019). PMID: 31305892 ↗

    L5OTHERCited in: Prevention, Screening & Surveillance
  565. [565]

    Sabatino JJ, Cree BAC, Hauser SL. “New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond.” Annals of neurology (2025). PMID: 40474602 ↗

    L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
  566. [566]

    . “Corrigendum.” Multiple sclerosis (Houndmills, Basingstoke, England) (2011). PMID: 22194215 ↗

    L5OTHERCited in: Prevention, Screening & Surveillance
  567. [567]

    Cohen M, Thomel-Rocchi O, Siva A et al.. “Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study.” Multiple sclerosis (Houndmills, Basingstoke, England) (2023). PMID: 37322880 ↗

    L2OTHERCited in: Prevention, Screening & Surveillance
  568. [568]

    Tamondong-Lachica DR, Villanueva CAG, Roxas-Timonera M et al.. “Philippine Clinical Practice Guidelines for Periodic Health Examination: Lifestyle Interventions for Adults and Adolescents.” Acta medica Philippina (2026). PMID: 42382939 ↗

    L5GUIDELINECited in: Prevention, Screening & Surveillance

Revision History

All updates applied to this page

Loading revisions…